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Abstract 
CD8+ T cells play pivotal roles in anti-viral immunity. In particular, CD8+ T cells that 
make high avidity interactions with virus-infected cells are extremely efficient in 
controlling virus infections including human immunodeficiency virus (HIV)-1. 
Therefore, induction of high avidity anti-viral CD8+ T cells following vaccination is 
expected to be beneficial for conferring protection against HIV -1. 
Our laboratory has shown that mucosal HIV -1 recombinant pox viral prime-boost 
vaccination can induce HIV-specific CD8+ T cells with reduced interleukin (IL )-4 and 
IL-13 cytokine expression and higher avidity compared to systemic vaccine delivery. 
To understand how these cytokines regulated CD8+ T cell avidity, the PhD studies 
initially evaluated the expression of receptors for these cytokines on immune cells using 
flow cytometry following a range of viral infections ( e.g. pox viruses and influenza 
virus) in mice. Results indicated that unlike other IL-4/IL-13 receptor subunits, IL-4 
receptor a (IL-4Ra) was significantly down-regulated on anti-viral CD8+ T cells in a T 
cell receptor (TCR) and cognate antigen dependent manner. These studies also showed 
that up-regulation of IL-4Ra on na:ive CD8+ T cells most likely resulting from signal 
transducer and activator of transcription 6 (ST A T6) signaling correlated with poor 
avidity anti-viral CD8+ T cell cytokine responses. Poor avidity anti-viral CD8+ T cells 
that developed in this instance as well as following systemic HIV-1 recombinant pox 
viral prime-boost vaccination expressed lower CD8 co-receptor densities. Interestingly, 
mucosal and IL-13 inbjbitor HIV-1 recombinant pox viral prime-boost vaccination 
strategies prevented significant down-regulation of CD8 densities and enhanced avidity 
of anti-viral CD8+ T cells. Collectively, data suggest that enhancing responsiveness of 
na:ive CD8+ T cells to IL-4 and IL-13 (i.e. up-regulation of IL-4Ra) primes poor avidity 
.. 
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anti-viral CD8+ T cells with reduced CD8 densities during vuus infection and 
recombinant HIV- I pox viral prime-boost vaccination. 
Given the poor capacity of current assays to evaluate CD8+ T cell avidity in vzvo 
following HIV-I vaccination, the current PhD studies also evaluated the use of a 
fluorescent target array (FT A) for this purpose. The FT A assay involves measuring in 
vivo T cell responses against peptide-pulsed splenocytes (targets) that have unique 
fluorescent signatures (e.g. over 200 signatures) after injection into vaccinated mice. 
This assay was utilized to effectively screen for 24 HIV- I recombinant pox viral 
vaccination regimens for the capacity to induce high avidity and epitope variant cross-
reactive CD8+ T cells as well as T helper (TH) responses in vivo. Overall, the FTA was 
found to be an extremely versatile assay for screening vaccines that could induce high 
quality T cell responses in vivo using pre-clinical models. 
Currently, the lack of knowledge regarding mechanisms that_ affect CD8+ T cell avidity 
and methods that evaluate CD8+ T cell avidity in vivo is a major barrier for developing 
efficacious HIV -1 vaccines. Therefore, the findings from the PhD research studies 
regarding how IL-4 and IL-13 regulate avidity and the use of a FTA to measure avidity 
in vivo could be exploited to foster future development of more efficacious HIV -1 
vaccines. 
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Chapter 1 
Introduction 
1 
1.1 Context of the study 
HIV-1, the causative agent of the acquired immunodeficiency syndrome (AIDS), has to 
date claimed over 25 million lives and over 34 million people are thought to be 
currently infected with this virus globally [UNAIDS World AIDS Day Report, 2012]. 
Although numerous care and treatment programmes including the use of anti-retroviral 
therapy (ART) are currently in place to suppress this global epidemic, the development 
of a vaccine is deemed essential to effectively eradicate HIV-1 [McElrath, 201 OJ. The 
development of a rationale HIV -1 vaccine is mainly impeded by the fact that an exact 
correlate of protection against this virus is unknown owing mainly to the capacity of 
HIV-1 to mutate rapidly and maintain latency [McMichael et al. , 2010]. However, 
several studies have isolated immune correlates that could provide effective resistance 
against HIV-1 [Critchfield et al., 2007; Walker et al. , 2009; Haynes et al. , 2012; Julien 
et al. , 2013; Liao et al., 2013; Turk et al., 2013]. In particular as will be described in 
detail later, developing vaccination strategies that facilitate the development of high 
avidity anti-viral CDS+ T cells are promising given that these cells are extremely 
efficient at controlling virus infections [Virgin and Walker, 201 OJ. 
Our laboratory findings collectively suggest that mucosal compared to systemic HIV-1 
recombinant pox viral prime-boost vaccinations promote the development of high 
avidity anti-viral CDS+ T cells most likely due to lesser induction of avidity dampening 
cytokines IL-4 and IL-13 [Ranasinghe et al., 2007; Ranasinghe et al. , 2009J. This is 
also in agreement with Ranasinghe et al [2013J recent study where mucosal 
vaccinations with novel HIV-1 recon1binant pox viral vectors that co-express an IL-13 
inhibitor protein (soluble IL-13 receptor a2 (IL-13Ra2~10) were shown to enhance 
anti-viral CDS+ T cell avidity. Recombinant pox virus vaccine vectors are commonly 
incorporated in HIV-1 prime-boost vaccination regimens in human clinical trials. 
,, 
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Therefore, understanding how IL-4 and IL-13 regulate anti-viral CD8+ T cell avidity 
following pox viral infections and vaccinations is expected to be important for 
developing effective HIV-I prime-boost vaccination regimens. Furthermore, 
engineering screening tools that can effectively evaluate avidity in vivo is also important 
for this purpose especially for HIV- I vaccination regimens that aim to induce high 
avidity anti-viral CD8+ T cells in vivo. 
1.2 The immune system: an overview of innate and adaptive immunity 
1.2.1 Overview 
Many infectious microorganisms (i.e. pathogens) such as viruses need to infect a certain 
host in order to survive. Once pathogens circumvent the numerous host physical barriers 
of infection ( e.g. epithelial surfaces, skin, mucus, saliva, tears, etc.), the functioning of 
the immune system is critical for limiting/eliminating pathogen infections from the host. 
In vertebrates, the immune system is comprised of innate and adaptive components; the 
roles of these components in controlling pathogen infections will be overviewed in this 
section. 
1. 2. 2 Innate immunity: the first line of immune defense against pathogens 
All cells of the blood including the immune system are derived from hematopoietic 
stem cells in the bone marrow through a process referred to as hematopoiesis [Sabin et 
al. , 1936]. During hematopoiesis, various cell types with the potential of exerting 
effector functions and/or initiating adaptive immune responses against pathogens 
emerge (table 1.1). In innate immunity, macrophages, dendritic cells (DCs), 
neutrophils, basophils, mast cells, natural killer (NK) cells, mucosal-associated invariant 
T (MAIT) cells, nuocytes, y6 T cells and NK T (NKT) cells respond immediately (i.e. 
3 
Table 1.1. Key functions of major cell types involved in the immune system. 
Cell type Key functions in immunity Reference 
Macrophages ••• • Destroy pathogens via phagocytosis, rutnc oxide a 
production or anti-microbial peptide production 
••• 
• Present antigens to T cells to help initiate adaptive 
immunity 
••• • Induce inflammation 1ll response to pathogen 
infections to recruit other immune cells 
DCs ••• • Present antigens to T cells to help initiate adaptive 0 
immunity 
N eutrophils ••• Trap and destroy bacteria . extrusion of IT • via 
chromatin fibers and phagocytosis 
••• • Induce inflammation 1ll response to pathogen 
infections to recruit other immune cells 
Basophils, ••• • Produce toxic proteins (e.g. histamines) and n 
eosinophils enzymes to destroy parasitic worm infections 
and mast cells ••• • Induce allergic inflammatory reactions in some 
instances such as asthma 
NK cells ••• • Recognize and mediate cytolysis of pathogen- b. 
infected or tumor cells to control infection or 
tumor growth 
NKT cells ••• • Produce immunoregulatory cytokines to help clear ~ 
bacterial/parasitic infections and tumors 
••• 
• Lysis of tumors 
MAIT cells ••• • Recognize conserved bacterial-derived ligands and YI 
protect hosts against bacterial infections 
Nuocytes ••• • Produce type-2 cytokines such as IL-13 to help Jt 
expel helminth infections 
yb T cells ••• • Produce cytokines such as IFN-y and IL-1 7 and B 
exert cytotoxic responses to help resolve tumors 
and pathogen infections 
Tregs ••• • Remove T cell clones that can react against self so § 
as to prevent autoimmunity 
••• • Shut down 1mmune responses to prevent 
immunopathology 
CDS+ T cells ••• • Adaptive recognition and cytolysis of pathogen- t 
infected cells or tumors to control infection or 
tumor growth 
CD4+ T cells ••• • Produce cytokines that help activate and regulate € 
the function of other immune cells such as B cells, 
macrophages and CD8+ T cells 
B cells ••• • Produce antibodies that prevent infection of cells ¥ 
by pathogens 
••• • Produce antibodies that can opsonize pathogens for 
phagocytosis 
a [Evans et al. , 1914; Murray and Wynn, 2011] 
0 [Steinman and Cohn, 1973; Steinman and Witmer, 1978] 
TI [Page and Good, 1958 ; Kaplan and Radie, 2012] ; n [Rothwell and Dineen, 1972; Akdis, 2012] 
6. [Kiessling et al., 1975 ; Jost and Altfeld, 2013] ; ~ [Sumida et al. , 1984; Godfrey et al. , 2000] 
ri [Le Bour his et al. , 201 OJ ; n [Neill et al. , 201 OJ; f3 [Born et al. , 2006] 
§ [Sakaguchi, 2004] ; t [Cerottini et al. , 1970; Freedman et al. , 1972; Zinkemagel et al. , 1974] 
€ [Cantor and Boyse, 1975 ; Abbas et al. , 1996] ; ¥ [Andersson et al. , 1972; Ahmed and Gray, 1996] 
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within hours) following pathogen exposure to either destroy or limit systemic spread of 
pathogens (table 1.1; figure 1.1). Macrophages and DCs cells are also professional 
antigen presenting cells (APCs) [Mosier, 1967; Steinman and Witmer, 1978]. Following 
pathogen ingestion, these APCs undergo maturation to express costimulatory 
molecules/danger signals (i.e. CD80/CD86) and present pathogen derived peptides on 
major histocompatibility complexes (pMHC) to CD4+ and CD8+ T cells to initiate 
adaptive immune responses (figure 1.1) [Hathcock et al. , 1994]. Furthermore, a group 
of plasma protein forming the complement cascade as well as circulating natural 
immunoglobulin (Ig)M antibodies also function in innate immunity (figure 1.1). These 
proteins help to opsonize pathogens for destruction, induce inflammation to recruit 
other immune cells and induce antibody responses during adaptive immunity against 
pathogens (figure 1.1) [Baugmarth et al., 1999; Sprong et al. , 2004]. 
A seminal feature of all immune responses is the ability to distinguish self from non-self 
pathogen-associated components. Cells of the innate immune system use pattern 
recognition receptors (PRRs) for this purpose [Janeway and Medzhitov, 2002]. PRRs 
recognize evolutionary conserved pathogen-associated molecular patterns (P AMPs) 
such as bacterial lipopolysaccharides (LPS), bacterial flagellin, unmethylated CpG 
dinucleotide motifs, viral single/double-stranded RNA and viral DNA [Kawai and 
Akira, 2010]. Recognition of PAMPs in this instance triggers innate immune cells to 
exert effector functions (table 1.1) and induce inflammation to recruit other immune 
cells such as B and T cells of adaptive immunity to sites of infection [Iwasaki and 
Medzhitov, 2010]. 
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(9 @ 
MAIT Bashophil Neutrophil Mast cell Eosinophil NK cell NKT cell Nuocyte 
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yfJ T cell Macrophage DC Complement lgM 
Antigen presentation 
~ pMHC-1 0 pMHC-11 T ~~:~/ V TCR l CD28 
Nai'.ve CD4+ T cell 
Figure 1.1. Innate immune barriers to pathogen invasion. Once pathogens (i.e. 
bacteria, virus, parasite and fungi) and/or foreign proteins invade a host, the innate 
immune system acts immediately to combat these foreign invaders. Numerous cell types 
illustrated above ( also see table 1.1) together with plasma proteins (i.e. complement and 
IgM) collaboratively act to destroy pathogens and induce inflammation to recruit more 
immune cells. Furthermore, macrophages and DCs also present costimulatory molecules 
(CD80/CD86) and peptides from ingested pathogens on MHC-II or MHC-I to activate 
naYve CD4+ T cells or naYve CD8+ T cells respectively. Presentation of peptide antigens 
in this instance is important for initiating adaptive immune responses. 
6 
1. 2. 2 Adaptive immunity: lymphocyte selection and T cell activation 
Innate immunity is sufficient to clear most pathogen infections, but a second line of 
immune defense known as adaptive immunity is sometimes required for pathogens to be 
efficiently cleared (table 1.2). Adaptive immunity is mainly comprised of lymphocytes 
such as B cells, helper CD4+ T (TH) cells and CD8+ T cells (figure 1.2; table 1.1). 
Similar to PRRs of innate immune cells, B cells use the B cell receptor (BCR) or T cells 
use the TCR to recognize pathogens [Bentley and Mariuzza, 1996; Schamel and Reth, 
2000]. However, each B or T cell clone has a receptor with a unique specificity to 
antigens and the assembly process of these receptors allow a broader array of antigens 
to be recognized compared to PRRs [Burnet, 1959; Schatz and Swanson, 2011]. To 
eliminate self-reactive clones with the potential of causing autoimmunity BCRs or 
TCRs that recognize self-antigens with high avidity undergo apoptosis during 
development in a process referred to as central tolerance [Burnet, 1959; Miller, 1961 ; 
Derbinski et al. , 2001; Pieper et al. , 2012]. NaYve (i.e. foreign antigen inexperienced) B 
and T cell clones that have bypassed central tolerance then circulate in the periphery 
and drain into secondary lymphoid organs (i.e. spleen and lymph nodes) where mature 
APCs present antigens derived from pathogens. 
For naYve T cells to clonally expand and differentiate into effector cells at least two 
activation signals are required [Lafferty and Cunningham, 1975]. The first signal is 
derived following engagement of the TCR with cognate pMHC class I (pMHC-I) in the 
case of CD8+ T cells or cognate pMHC class II (pMHC-II) in the case of CD4+ T cells 
(figure 1.1). The second signal is derived following engagement of the CD28 co-
receptor on T cells with costimulatory molecules (CD80/CD86) on APCs, which is 
usually up-regulated on APCs following recognition of PAMPs (figure 1.1) [Hathcock 
et al. , 1994]. 
7 
Table 1.2. Key features that distinguish innate and adaptive immunity. 
Feature Innate immunity Adaptive immunity 
Major cell types involved Mast cells, neutrophils, ...L + T (CD4 ' and CD8 ) cells 
in pa tho gen defense macrophages, DCs, and B cells 
basophils, eosinophils, NK 
cells, NKT cells, MAIT 
cells, nuocytes and y6 T 
cells 
Lifespan of cells involved Short Long 
Pathogen recognition and Recognition is fixed Recognition is highly 
adaptability ( evolutionary conserved adaptive (specific 
features of pathogens (i.e. components of pathogens 
PAlvfPs)recognized recognized through TCR 
through PRRs) (T cells) or BCR (B cells)) 
Immunological memory Absent Present 
Speed of pathogen specific Shortly after pathogen Delayed in the absence of 
responses encounter (i.e. within immunological memory 
hours) (i.e. 4-7 days) 
Tolerance to prevent self Absent Present 
reactivity 
8 
Antibody secretion 
-c,., 
B cell 
0 
~ :::,-? ';).. y,G, 
?~-Cy 
~ -G ...c. 
:r 
,G, 
Essential help 
Successful neutralization 
}nfection prevented 
Virus peptide -¥\lit' Cytolysis 
TCR 
--------
Essential help 
Unsuccessful neutralization 
{J ..G ...c. 
,...c. r -c 
~ y 
""'C' 
~ 
..Gy 
Infection proceeds 
Neutralization of assembled virion 
Figure 1.2. Key functions of major cell types involved in adaptive immunity 
against virus (HIV-1) infection. CD4+ T cells, CD8+ T cells and B cells have all been 
known to play an important role in either preventing or limiting HIV-1 infection. B cells 
secrete antibodies with the potential to neutralize this virus. Successful neutralization 
requires antibodies to bind to the protruding viral envelope glycoproteins that are 
crucial for mediating viral entry into target cells. Failure to do so allows HIV-1 to infect 
target cells. Further infections with HIV -1 can be prevented or limited either via 
antibodies that can effectively neutralize newly assembled virions or via effector CD8+ 
T cells that can mediate cytolysis of infected cells following TCR mediated recognition 
of virus pMHC-I complexes. Effector CD4+ T cells provide help for efficient 
mobilization of B cell and CD8+ T cell mediated immune responses against HIV -1. 
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The costimulatory second signal (i.e. danger signal) appears to be required for na1ve T 
cells to up-regulate bcl-xL expression and survive during T cell activation [Boise et al., 
1995]. Interestingly, there are also studies to suggest that a distinct third signal (IL-1 in 
case of CD4+ T cells and type I interferons (IFN-I) or IL-12 in case of CD8+ T cells) is 
also required for optimal clonal expansion and effector differentiation of na1ve T cells 
[Curtsinger et al. , 1999; Curtsinger et al. , 2007]. 
Once na1ve T cells develop into armed effectors, only signal one ( cognate pMHC) is 
required for triggering of effector functions (figure 1.2). Some effector T cells· survive 
long after pathogen is cleared from the infected hosts and are referred to as memory T 
cells [Flynn et al. , 1998; Reinhardt et al. , 2001]. These cells can respond immediately 
after re-exposure with the same pathogen unlike na1ve T cells allowing for even more 
rapid clearance of the pathogen compared to the initial pathogen exposure. 
Overall, the immune system is comprised of a highly specialized network of cells that 
collaborate efficiently and exert various effector functions to eliminate foreign invaders 
(e.g. pathogens). This system is also specialized to distinguish self from non-self 
components allowing infected hosts to specifically destroy pathogens. 
1.3 Adaptive immunity against HIV-1 
1.3.1 Overview 
The hallmark of rationale vaccine design is to identify adaptive immune responses that 
can be protective against a pathogen and induce these responses using safe/attenuated 
vaccine vectors. In this section, the importance of adaptive immune responses involving 
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B cells (antibodies), CD8+ T cells and CD4 + T cells in the control of HIV -1 infections is 
discussed. 
1. 3. 2 Importance of antibodies against HIV-I 
All known viruses including HIV-1 need to infect cells in order to replicate and survive. 
The successful prevention of HIV-1 infections or trans-infection of target cells ( e.g. 
DCs and CD4+ T cells) is mainly reliant on the availability of HIV-1 neutralizing 
antibodies [McDonald et al., 2003; Yu et al., 2008; Mascola and Montefiori, 2010]. To 
infect cells, HIV-1 envelope proteins need to interact with the CD4 receptor and the co-
receptor C-C chemokine receptor 5 (CCR5)/CXC-chemokine receptor-4 of cells 
[Dalgleish et al., 1984; Deng et al., 1996; Bleul et al., 1996]. Neutralizing antibodies 
that bind to the viral surface envelope protein usually prevent this interaction and 
infection of cells (figure 1.2) [Lasky et al., 1986; Weiss et al. , 1986]. Binding of 
antibodies to the viral envelope of viruses about to bud out from infected cells could 
also neutralize viruses through activation of NK cell antibody-dependent cellular 
cytotoxicity (ADCC) machinery [Chung et al., 2011; Haynes et al. , 2012; Tomaras et 
al., 2013]. Although HIV-1 neutralizing antibodies are known to occur following 
natural infection with this virus, these antibodies are largely ineffective owing to 
extensive mutations, glycosylation and conformational masking of the envelope protein 
[Kwong et al., 2002; Dhillon et al. , 2007; Mascola and Montefiori, 2010]. Given that 
the ancestor of HIV-1, simian immunodeficiency virus (SIV), can be transmitted as a 
cell-associated form, HIV-1 might also be transmitted in a similar manner in which case 
neutralizing antibodies could be ineffective [Sodora et al., 1998]. Nonetheless, 
numerous research groups have recently identified monoclonal antibodies even during 
natural infections that bind to conserved regions of HIV -1 envelope and neutralize a 
broad spectrum of HIV-1 quasi-species [Zhou et al., 2010; Walker et al. , 2011; Huang 
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et al. , 2012; Julien et al. , 2013; Liao et al. , 2013]. The discovery of these broadly 
neutralizing antibodies has generated much enthusiasm and hope for the development of 
HIV-1 vaccines. 
1. 3. 3 Importance of CD8+ T cells against HIV-I 
If antibodies fail to prevent HIV-1 infection then effector CD8+ T cells play a crucial 
role in limiting further infections (figure 1.2). Upon recognition of cognate pMHC-I, 
effector CD8+ T cells mediate apoptosis of virus-infected cells either through the 
interaction of Fas ligand with Fas on target cells or through the release of cytolytic 
granules (e.g. perforin and granzymes) [Lieberman, 2003]. Lysis of infected cells 
prevents further viral replication and results in the release of immature HIV-1 virions, 
which are rapidly degraded in the extracellular milieu [Walker and Burton, 2008]. To 
date, the best vaccines that confer protection against SIV in simian models are live 
attenuated SIV vaccines [Daniel et al. , 1992]. A recent study by Fukuzawa et al [2012] 
suggests that protection of macaques that were vaccinated with various live attenuated 
vaccines was dependent on effector-differentiated CD8+ T cell responses in the lymph 
nodes. A few studies from the same group where macaques were vaccinated with a 
persistent recombinant rhesus cytomegalovirus prior to SIV challenge also suggest that 
CD8+ T cell responses could protect against SIV challenge [Hansen et al. , 2011; Hansen 
et al. , 2013]. Data from simian models suggest that CD8+ T cells could play pivotal 
roles in protection against HIV-1. The effectiveness of CD8+ T cells in suppressing 
HIV-1 replication appears to be primarily due to responses against internal viral 
epitopes ( e.g. Gag) that are well conserved within and across viral subtypes [Yusim et 
al. , 2002; Robinson, 2002; Kunwar et al. , 2013]. Indeed, as will be discussed in section 
1.4 numerous studies have shown that elite controllers or long-term non-progressors 
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who are resistant to HIV-I following infection exhibit enhanced HIV Gag-specific 
CD8+ T cell activity (e.g. cytotoxicity, avidity and/or polyfunctionality) compared to 
more susceptible individuals [Pontesilli et al. , 1998; Betts et al. , 2006; Almeida et al., 
2007; Critchfield et al. , 2007; Ferre et al. , 201 O; Berger et al. , 2011 ; Turk et al. , 2013]. 
1. 3. 4 Importance of CD4+ T cells against HIV-I 
HIV-specific CD4+ T cells appear to be particularly susceptible for HIV-I infection and 
memory CD4+ T cells given their long life-span are ideal reservoirs for viral latency 
[Douek et al., 2002; Bosque and Planelles, 2009; Perreau et al. , 2013]. Despite this, 
CD4+ T cell activation may yet be more favourable than detrimental to the HIV-I 
infected host [Virgin and Walker, 2010]. This is especially true given that TH cells help 
activate B cells and appear to provide essential help ( e.g. IL-21 secretion, sustaining 
CD8+ T cell cytotoxicity and mucosa! homing) to CD8+ T cells responding against HIV-
I [Virgin and Walker, 2010; Chevalier et al. , 2011]. The requirement of CD4+ T cells 
for combating HIV-I is still a controversial issue given that the presence of CD4+ T 
cells at sites of HIV-I infections may fuel virus replication, but CD4+ T cell help is 
known to be required for optimizing B cell and CD8+ T cell responses. 
1.4 CD8+ T cell avidity: definition, mechanisms and importance in HIV-1 control 
CD8+ T cell avidity or functional avidity is classically defined by the amount/strength of 
cognate pMHC-I interaction required to trigger effector responses with high avidity 
cells capable of responding to lower amounts of cognate pMHC-I than low avidity 
counterparts (figure 1.3) [ Alexander-Miller et al. , 1996; Zeh et al. , 1999; Derby et al., 
2001]. High avidity anti-viral CD8+ T cells also appear to produce higher amounts of 
anti-viral cytokines interferon (IFN)-y, tumour necrosis factor (TNF)-a and IL-2 
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Figure 1.3. High avidity COS+ T cells control virus infections more efficiently than 
low avidity COS+ T cells. Early on following viral infection of a target cell, lower 
levels of viral proteins are produced and presented on MHC-I molecules compared to a 
infected target cell at a later phase. Therefore at early stages of infection high avidity 
CD8+ T cells respond against infected cells given that these cells require lower amounts 
of cognate pMHC-I than low avidity CD8+ T cells to trigger effector functions (i.e. 
cytolysis and production/secretion of cytokines ). High avidity CD8+ T cells are also 
polyfunctional and produce/secrete TNF-a, IFN-y and IL-2. Low avidity CD8+ T cells 
can only mediate cytolysis of infected target cells at a later phase where these cells 
express greater amounts of cognate viral pMHC-I than early-infected cells. Hence, low 
avidity CD8+ T cells are poor controllers of virus infection. Low avidity CD8+ T cells 
are also thought to be poorly polyfunctional and produce low levels of IFN-y, but not 
significant levels of TNF-a and IL-2. 
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compared to low avidity anti-viral CD8+ T cells [Almeida et al., 2007; Almeida et al. , 
2009]. Thus, high avidity anti-viral CD8+ T cells are expected to respond against virus-
infected cells much earlier during infection and control viral infections more efficiently 
than low avidity anti-viral CD8+ T cells. 
There are several cell-associated components that could regulate the functional avidity 
of CD8+ T cells. Components/molecules that have been reported to enhance the 
functional avidity include: 1) increasing TCR affinity to pMHC-I [Busch and Pamer, 
1999], 2) enhancing expression levels of TCR, CD8 a~ co-receptor and adhesion 
molecules such as CD2 and CD1 la [Springer et al., 1987; Alexander et al. , 1991; Viola 
and Lanzavecchia, 1996], 3) increasing cholesterol content to allow the formation of 
lipid rafts [Fahmy et al., 2001], and 4) amplifying intracellular signalling through 
enhanced expression or activity of molecules such as lymphocytic-specific protein 
tyrosine kinase (lck) [Bachmann et al., 1999; Slifka and Whitton, 2001]. The expression 
levels, affinity or activity of these molecules could also be down-regulated to reduce the 
functional avidity of CD8+ T cells. There are also several inhibitory molecules that 
could serve to reduce the functional avidity of CD8+ T cells. These include CD5 
mediated inhibition of TCR signalling [ Azzam et al., 1998; Perez-Villar et al., 1999] 
and expression of molecules that can exhaust the function of CD8+ T cells such as 
programmed death-I and cytotoxic T lymphocyte-associated antigen-4 [Nakamoto et 
al. , 2009]. 
Despite the knowledge regarding molecules that can regulate functional avidity, the 
mechanisms involved in modulating functional avidity of anti-viral CD8+ T cells are not 
thoroughly understood and appear to be dependent on the virus infection. Following 
lymphocytic choriomenangitis virus (LCMV) infections, enhancing lck expression is a 
feature of LCMV-specific CD8+ T cells undergoing avidity maturation [Slifka and 
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Whitton, 2001]. During pox virus infections enhancement in CD8a~ co-receptor 
densities have been predictive of avidity maturation of anti-viral CDS+ T cells [Oh et 
al., 2004; Xiao et al. , 2007]. Furthermore, qualitative differences in TCR 
assembly/clonotypes (i.e. use of V~7) rather than enhancement in expression of 
molecules such as TCR, CDS, lck, CD 11 a and CD2 are predictive of avidity on 
influenza-specific CDS+ T cells [Kedzierska et al. , 2005; La Gruta et al. , 2006]. There 
are also various other CDS+ T cell extrinsic factors that could regulate anti-viral CDS+ T 
cell avidity. These include Tregs [Pace et al. , 2012] , cytokines (e.g. IL-4, IL-12, IL-13 , 
IL-15 and IFN-I) [Xu et al. , 2003; Oh et al. , 2004; Xiao et al. , 2007; Ranasinghe et al. , 
2009], DC costimulation [Oh et al. , 2003; Hodge et al. , 2005] and DC subsets 
[Ranasinghe et al., 2013]. Overall, regulation of anti-viral CDS+ T cell avidity is 
dependent on the context of virus infection and is multifactorial. 
During HIV-1 infections, high avidity HIV-specific CDS+ T cells appear to be important 
to minimise or prevent the spread of HIV-1 from early-exposed sites ( e.g. genito-rectal 
mucosa) to the gut where the greatest CD4+ T cells depletion occurs [Wijesundara et al. , 
2011]. Several studies in macaques suggest that high avidity anti-viral CDS+ T cells can 
protect against SIV [Belyakov et al., 2001 ; Belyakov et al. , 2006; Belyakov et al. , 
2007]. Furthermore, numerous studies have suggested that resistance to HIV-1 infection 
in elite controllers correlates with enhanced high avidity and polyfunctional HIV-1 Gag-
specific CDS+ T cell responses [Pontesilli et al. , 1998; Betts et al. , 2006; Almeida et al. , 
2007; Critchfield et al., 2007; Ferre et al., 2010; Berger et al. , 2011 ; Turk et al. , 2013]. 
High avidity HIV-specific CDS+ T cells also have the capacity to recognize mutant viral 
epitopes and are therefore highly cross-reactive [Mothe et al. , 2012]. Overall, high 
avidity HIV-specific CDS+ T cells appear to play critical roles in protection against 
HIV-1. 
,, 
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1.5 Strategies for developing a functional cure against HIV-1 
1. 5.1 Overview 
Worldwide HIV-1 currently has infected over 60 million people and claims 2.5 million 
new infections every year [UNAIDS Special Report, 2013] . Given the latency capacity 
of this virus it is extremely difficult to develop a complete cure against HIV-1 . 
However, therapeutic or prophylactic approaches that can reduce viral loads to 
undetectable levels and maintain an infected individual ' s health similar to that of an 
uninfected individual are deemed achievable. These approaches are referred to as 
strategies for developing a functional HIV-1 cure [Deeks et al. , 2012]. Here the 
prospects of the three major approaches (stem cell therapy, ART and vaccination) for 
developing a functional cure against HIV -1 are briefly reviewed. 
1. 5. 2 Stem cell therapy against HIV-] 
Some Caucasians express a truncated version of CCR5 (homozygous 32-base-pair 
deletion of CCR5 (CCR5~32)) that allow them to effectively resist HIV-1 infections 
[Samson et al., 1996]. This knowledge was used by a team of transplant surgeons in 
Germany to treat a patient (referred to as the "Berlin Patient") who was suffering from 
leukaemia and HIV-1 infection [Hutter et al. , 2009]. Subsequently, the first ever HIV-1 
cure was announced due to the Berlin Patient receiving allogenic hematopoietic stem 
cell transplantation from a CCR5~32 donor [Hutter et al. , 2009]. However, grand-scale 
therapeutic application of this curative strategy is expected to be limited due to the lack 
of MHC-matched donors, toxicity and cost. To circumvent these issues, researchers are 
currently developing cost-effective gene therapy strategies to knockout CCR5 
expression on T cells and hematopoietic stem cells for autologous transplantation 
purposes [Cannon and June, 2011]. 
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1. 5. 3 Anti-retroviral therapy against HIV-I 
The use of drugs such as ART or combined ART ( cAR T) for inhibiting various stages 
of the virus life cycle ( e.g. inhibiting viral reverse transcriptase, protease and integrase 
activity) have been the most successful strategy to treat HIV-infected individuals 
[Volberding and Deeks, 201 OJ. These strategies under strict patient adherence can be 
used to functionally cure HIV-1 infected individuals: reduce HIV-1 viral loads to 
undetectable levels, improve CD4+ T cell counts and survival of HIV-1 infected patients 
[UNAIDS World AIDS Day Report, 2012]. A recent clinical trial (HPTN 052) also 
showed that early (350-550 CD4+ T cells/mm3 blood) compared to late (<250 CD4+ T 
cells/mm3 blood) cAR T treatment of HIV-1 infected individuals significantly reduces 
HIV-1 transmission in serodiscordant couples [Cohen et al. , 2011]. Early diagnosis and 
treatment with ART drugs (e.g. Raltegravir) that inhibit viral DNA integration into the 
genome of host CD4 + T cells could also be important in preventing significant loss of 
CD4+ T cells during acute phase infections [Cooper et al., 2013]. Thus, 
immunodeficiency related deaths or morbidity resulting from opportunistic co-
infections such as tuberculosis, hepatitis, malaria and cryptococcosis might also be 
averted from early cART treatment [Chang et al. , 2013]. 
Despite the enormous potential and success of cAR T, its use to treat about 34 million 
HIV-1 infected individuals is deemed to be too costly and difficult to sustain especially 
given that drugs in cART regimens need to be taken on a daily basis [Andrieux-Meyer 
et al. , 2012]. Ideally, a true functional cure will also not require life-long treatment and 
an immune intervention following cART treatment to bolster durable suppressive anti-
viral immune responses might be required to improve the feasibility of using cAR T as a 
functional cure. There have also been reports of HIV-1 drug resistance [Masimba et al. , 
2013], lack of patient adherence to cART regimens [Charurat et al., 2010] and adverse 
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side-effects associated with the use of cART [Rather et al., 2013]. Furthermore, cART 
cannot be used to deplete latent reservoirs ofHIV-1 [Vandergeeten et al. , 2013]. 
1.5.4 Vaccination against HIV-1 
Since Edward Jenner pioneered vaccination during the 19th century, vaccines have been 
used to eradicate smallpox and prevent human infections such as measles, polio and 
yellow fever [Fenner et al., 1988; Rueckert and Guzman, 2012]. For HIV-1 , vaccines 
can be used for immunoprophy laxis and are also expected to be much more cost-
effective than ART especially given that vaccines have the potential to induce long-
lasting protective immune responses. However, historically the use of vaccines in phase 
Ilb (STEP trial) and phase III (VAX003 , V AX004 and RV144) HIV-1 human clinical 
trials have been met with failure to induce significant protective outcomes [Flynn et al. , 
2005; Pitisuttithum et al. , 2006; Buchbinder et al. , 2008; Rerks-Ngarm et al. , 2009]. 
The lack of natural immunity and immune correlates of protection against HIV -1 have 
also impeded progress for developing a HIV-1 vaccine [Wijesundara et al. , 2011 ; Sanou 
et al. , 2012]. Furthermore, the reasons for poor translatability of findings in animal 
models and the failures of HIV-1 vaccines tested in human clinical trials are unclear. 
For instance, it was thought that the Adenovirus serotype 5 (Ad5) vaccine vector used in 
the STEP trial induced protective CD8+ T cell responses in macaques, but not in 
humans due to pre-existing immunity against Ad5 in humans [Cohen, 2013]. However, 
the recent failure of the HVTN 505 trial suggests that this was not the case and the use 
of Ad5 for vaccination in humans could increase the risk of HIV-1 acquisition [Cohen, 
2013; Hammer et al. , 2013]. Furthermore, the vaccine used in this trial was ineffective 
in inducing Gag-specific CD8+ T cell responses and predominantly induced CD8+ T cell 
responses against the highly variable HIV-1 envelope protein [Hammer et al. , 2013]. 
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Less than 1 % of HIV-infected individuals, referred to as elite controllers, have the 
capacity to control HIV-1 effectively to undetectable levels (usually <50-75 viral RNA 
copies per ml of plasma) [Deeks and Walker, 2007]. Therefore, understanding immune 
responses that allow elite controllers to resist HIV -1 infections and developing vaccines 
that will induce these responses is a rationale path for developing a HIV -1 vaccine. As 
discussed in section 1.3 and 1.4, the responses elucidated thus far that correlate with 
resistance include HIV-1 broadly neutralizing antibodies and high 
avidity/polyfunctional CD8+ T cell responses particularly against HIV-1 Gag epitopes. 
Apart from elite controllers understanding immune correlates of protection in the 
RV144 clinical trial, which reported a 30% protective efficacy is another attractive 
approach for developing a HIV-1 vaccine [Rerks-Ngarm et al. , 2009]. In the RV144 
trial the induction of IgG, but not IgA antibodies against HIV-1 envelope that help 
mediate ADCC in vaccinated individuals have correlated with protection [Haynes et al. , 
2012; Tomaras et al. , 2013]. Overall, mucosal (e.g. transmission sites like genito-rectal 
mucosa) and systemic induction of broadly neutralizing antibodies, ADCC antibodies 
and high avidity CD8+ T cells that respond against conserved HIV -1 antigens are all 
promising targets when designing prophylactic HIV-1 vaccines. 
The use of therapeutic vaccines to boost HIV-specific immune responses and reduce 
viral loads in HIV -1 infected individuals could be difficult due to several reasons: 1) 
pre-existing immunity and/or high viral loads could reduce lymphocyte proliferation 
[Moss et al. , 2002], 2) continuous immune stimulation can lead to anergy and immune 
exhaustion [Day et al. , 2006; Carcelain and Autran, 2013] , 3) the existence of escape 
mutants of immune surveillance [Geels et al. , 2003] , and 4) latent viral reservoirs can be 
found in immunologically privileged sites and expansion of CD4+ T cells could increase 
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the number of viral reservous [Pierson et al. , 2000]. Passive transfer of broadly 
neutralizing antibodies and vector-based immunoprophylaxis are emerging novel 
approaches that could be more successful for therapeutic purposes [Nishimura et al. , 
2003; Balazs et al., 2012; Diskin et al. , 2013]. Given that neutralizing antibodies can be 
engineered to have a long half-life in vivo [Zalevsky et al. , 201 O], these approaches 
could also be cost-effective surrogates for cART treatment. 
The use of vaccines for prophylactic and therapeutic purposes is expected to be more 
cost-effective and sustainable for developing a functional cure against HIV-1 than 
cAR T. Rationale vaccine design against HIV -1 will require vaccines that will 
effectively induce immune responses that correlate with HIV-1 resistance in elite 
controllers and protection in the RV 144 clinical trial. However, this is not 
straightforward and requires detailed understanding of mechanisms that facilitate the 
induction of high avidity CD8+ T cells, broadly neutralizing antibodies and ADCC. 
1.6 Poxviruses: why are they ideal vaccine vectors? 
Since Edward Jenner inoculated individuals with cowpox virus to confer protection 
against smallpox, the use of pox viruses for developing vaccines against numerous 
deadly pathogens such as malaria, influenza and HIV -1 is currently commonplace. 
Significant efforts have also been devoted for the use of recombinant Ad5 vectors for 
HIV -1 vaccination in humans, but recent clinical trials suggest that Ad5 vectors could 
increase the risk of HIV -1 acquisition and are not safe for human use [Buchbinder et al. , 
2008; Cohen, 2013]. The characteristics of pox viruses are described thoroughly in 
McFadden [2005] and summarized in table 1.3. Amongst the two subfamilies, species 
belonging to the Chordopoxvirinae (table 1.3) are used for vaccine development and 
the features that make them ideal for this purpose are listed below: 
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1) These viruses have large genome and packaging flexibility allowing for deletion of 
large amounts of viral DNA (at least 25 kb) for insertion of multiple 
antigens/adjuvants of interest [Smith and Moss, 1983]. 
2) They induce robust long-lasting T and B cell responses even after a single 
inoculation [Gherardi and Esteban, 1999]. 
3) Recombinants of these viruses can be easily grown and stored freeze-dried making 
them easy to manufacture and administer [Collier, 1955]. 
4) Pox viruses are safe or can be engineered ( e.g. deletion of virulent genes) to be safe 
for use in humans. 
•!• Recombinant A vi pox viruses such as fowlpox virus (FPV) and canarypox virus 
do not replicate in human cells and are safe for use in humans [Boyle et al. , 
2004; Pitisuttithum, 2005; Kelleher et al. , 2006]. 
•!• Thymidine kinase deficient strains of vaccinia virus (VV) and attenuated strains 
of VV such as Copenhagen strain of New York VV (NYV AC) and modified 
vaccinia Ankara (MV A) that do not replicate in human cells are safe for use in 
humans [Moss, 1996]. 
5) Pox viruses when used as vaccines have rendered protective outcomes against 
human and animal diseases. Few examples are listed below: 
•!• VV was used for the global eradication of smallpox [Fenner et al., 1988]. 
•!• Recombinant VV vaccines were used to vaccinate wild foxes to reduce rabies 
incidences in Europe [Pastoret et al. , 1988]. 
22 
Table 1.3. Characteristics of pox viruses. 
Characteristic Description . 
Subfamilies Two subfamilies: 
1. Chordopoxvirinae (infects vertebrates) 
2. Entopoxviridae (infects invertebrates/insects) 
Genera of Eight genera for Chordopoxvirinae: 
Chrodopoxvirinae 1. Orthopox ( e.g. ectromelia, monkeypox, vaccinia and variola) 
2. Parapox (e.g. pseudocowpox and somatitis papulosa) 
3. A vipox ( e.g. canarypox, fowl pox and quailpox) 
4. Capripox ( e.g. goatpox and sheep pox) 
5. Leporipox ( e.g. myxoma) 
6. Suipox ( e.g. swinepox) 
7. Molluscipox ( e.g. molluscum contagiosum) 
8. Y atapox ( e.g. tanapox) 
Genome Linear double stranded DNA genome (130-300 kb) with a 
hairpin loop at each end 
Size -300 nm 
Morphology Ovoid or brick-shaped enveloped viruses 
Replication Exclusively in the cytoplasm of cells 
Host range Host range depends on the species of virus ( e.g. ectromelia virus 
(mice), FPV ( chicken), variola virus (humans) and VV (natural 
host unknown, but infects human and mice) 
Transmission Most commonly transmitted through inhalation of virus droplets, 
but can also be transmitted through direct skin contact 
Genetic Considerable genetic similarities between different virus species: 
similarities ••• • -50-75% of genes are conserved between all species of 
Chordopoxvirinae 
••• -25% of genes conserved between all . of • are species 
Chordopoxvirinae and Entopoxviridae 
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•!• Recombinant FPV have been used to protect Australian poultry against 
infectious burs al disease virus [Boy le and Heine, 1994]. 
•!• In the RV 144 Thai trial where protection against HIV -1 was reported, HIV -1 
recombinant canarypox virus was used to vaccinate human participants [Rerks-
N garm et al., 2009]. 
1. 7 Prime-boost vaccination to generate high avidity HIV-specific CDS+ T cells 
1. 7. 1 Overview 
Prime-boost vaccination is a consecutive immunization strategy used to amplify the 
number of antigen-specific effector/memory lymphocytes responding against encoded 
vaccine antigens (figure 1.4). The use of heterologous vectors in this instance is 
desirable to minimise the effects of anti-vector immunity that could occur if genetically 
identical (i.e. homologous) vectors are used for the prime and the booster vaccinations 
[Leong et al., 1995; Ramsay et al., 1997; Kent et al., 1998; Wijesundara et al., 2012]. 
Since its inception, heterologous prime-boost vaccination strategies have been used in 
an attempt to generate protective immunity against diseases such as malaria, 
tuberculosis, influenza and HIV-1 [Wijesundara et al., 2012]. However, there are 
various parameters that have to be optimized for developing efficacious heterologous 
prime-boost vaccination regimens [Wijesundara et al., 2012]. Here, ways to manipulate 
vaccination route, vector choice and molecular adjuvants such that heterologous prime-
boost vaccination regimens can generate high avidity anti-viral CD8+ T cells are briefly 
reviewed. 
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Figure 1.4. Heterologous prime-boost vaccination for generating T cell immunity. 
Heterologous prime-boost vaccination involves immune priming and at least one 
immune boost to amplify immune responses of interest. A, In immune priming, antigens 
of interest (red) encoded in a recombinant DNA (rDNA) vector or a live virus vector 
(i.e. recombinant FPV (rFPV)) is used for immunization. Suosequently, vector encoded 
antigens gets presented by AP Cs to naYve T cells, which facilitates naYve T cell 
activation and differentiation into effector/memory T cells. Following immune priming, 
the peripheral T cell pool is expected to comprise primarily of naYve T cells (green) and 
relatively small proportion of effector/memory T cells specific to the encoded vaccine 
antigens of interest (red) or T cells specific to other vector components (blue). B, In 
immune boosting, same vaccine antigens (red) are delivered in a heterologous viral 
vector such as recombinant MVA (rMVA) to minimise the anti-vector immunity. 
Hence, following heterologous booster immunization the number of effector and 
memory T cells against the desired vaccine antigens gets further expanded. 
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1. 7. 2 Route of vaccine delivery: mucosa! versus systemic 
Most pathogens including HIV-1 are encountered at the mucosa and generating 
protective mucosal immunity is crucial for preventing the systemic spread of pathogens 
like HIV-1. Mucosal vaccination strategies are extremely effective in generating 
protective mucosal immunity against various mucosal pathogen infections [Belyakov 
and Ahlers, 2009]. This could be partially due to the capacity of mucosal vaccination 
regimens to generate high avidity anti-viral CD8+ T cells at mucosal surfaces. Indeed, 
several prime-boost vaccination studies have shown that mucosal (e.g. intranasal (i.n.) 
or intrarectal) compared to systemic (e.g. subcutaneous or intramuscular (i.m.)) vaccine 
delivery particularly during the prime is better at generating high avidity mucosal 
HIV /SIV-specific CD8+ T cells and protection [Belyakov et al. , 2001; Belyakov et al. , 
2006; Belyakov et al. , 2007; Ranasinghe et al. , 2007; Belyakov et al. , 2008; Ranasinghe 
et al. , 2011]. The exception here is when recombinant DNA vectors are used where i.m. 
priming is required for enhanced expression of vector encoded antigens [Wolff et al. , 
1990; Ranasinghe et al. , 2011]. Purely systemic vaccinations have failed to protect 
against HIV -1 in human clinical trials and are also poor at inducing mucosal homing 
marker (i.e. integrin a 4~ 7 and C-C chemokine receptor 9) expression and mucosal 
homing of T cells [Wijesundara et al. , 2011]. However, Ranasinghe et al [2007] have 
shown that combined mucosal/systemic (i.n. FPV-HIV primeNV-HIV boost) compared 
to purely mucosal (i.n. FPV -HIV /i.n. VV-HIV) regimens are more effective in 
generating high magnitude of HIV-specific CD8+ T cells. This was shown to occur in 
both mucosal and systemic compa1iments without significantly compromising T cell 
avidity [Ranasinghe et al. , 2007]. Overall, mucosal prime-boost vaccination regimens 
exhibit great potential for inducing high avidity HIV-specific CD8+ T cells and 
protection against HIV -1. 
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1. 7.3 Vaccine vector choice 
The choice of vectors for the prime and the boost could be a critical determinant for the 
avidity outcomes of anti-viral CD8+ T cells induced following prime-boost vaccination. 
For immune priming, non-replicating vaccine vectors (e.g. recombinant DNA or FPV) 
in mammalian cells that do not express high doses of vector-encoded antigens are 
desirable for obtaining protective outcomes and high avidity CD8+ T cells [Kent et al. , 
1998; Ramsay et al. , 1999; Ranasinghe et al. , 2011]. This is likely because the avidity 
of effector CD8+ T cells is expected be enhanced when their naYve precursors are 
primed with low doses of cognate antigens [Alexander-Miller et al. , 1996; Zeh et al. , 
1999]. However, a caveat is that using extremely low doses of antigen could be 
ineffective in priming T cell responses [Ranasinghe et al. , 2006]. For immune boosting, 
the use of recombinant live viral vectors is extremely effective in expanding desired 
anti-viral CD8+ T cell populations [Ramsay et al. , 1999; Ranasinghe et al. , 2006]. In 
particular, the use of recombinant VV for i.m. boosting especially following an i.n. 
prime with recombinant FPV have been established in our laboratory to be excellent at 
expanding high avidity anti-viral CD8+ T cells [Ranasinghe et al. , 2006; Ranasinghe et 
al. , 2007]. Overall, in vivo immune priming with vectors that express low levels of 
cognate antigens (e.g. recombinant DNA or FPV) prior to immune boosting with 
recombinant live viral vectors could be extremely effective in generating high avidity 
anti-viral CD8+ T cells. 
1. 7. 4 Vaccine adjuvants 
Historically adjuvants have been incorporated to enhance the immunogenicity of 
vaccines, but very few adjuvants are known to enhance the avidity of CD8+ T cells 
given that mechanisms dictating T cell avidity are poorly understood [Wijesundara et 
al. , 2012]. A few studies suggest that enhancing costimulatory capacity and maturation 
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of DCs through immunization with recombinant pox viruses containing T cell 
costimulatory molecules and/or granulocyte-macrophage colony stimulating factor are 
effective in inducing high avidity CD8+ T cells that can protect against tumors [Oh et 
al. , 2003 ; Hodge et al. , 2005]. Belyakov et al [2001; 2006] suggest that helper-CD8+ T 
cell peptide vaccination strategies adjuvanted with E.coli labile toxin can also enhance 
avidity of anti-viral CD8+ T cells and protection of macaques against SIV. In our 
laboratory, Ranasinghe et al [2013] showed that i.n./i.m. prime-boost vaccination with 
HIV-1 recombinant pox viral vaccines adjuvanted with IL-13 inhibitor (IL-13Ra2~10) 
can enhance the avidity of Gag-specific CD8+ T cells and protection. In Ranasinghe et 
al [2013] mucosal (i.n.) priming with recombinant IL-13 inhibitor FPV vectors were 
also shown to enhance the recruitment of a distinct subset of CD 11 b + CD 11 c + DCs into 
the lung, which is currently being evaluated for the capacity to prime high avidity CD8+ 
T cells. Thus, given that nai:ve T cell priming conditions can dictate avidity outcomes 
adjuvants can be used to alter the priming milieu such that high avidity anti-viral CD8+ 
T cells develop. 
1.8 IL-4 and IL-13: regulation of T cell avidity and cellular signaling 
IL-4 and IL-13 share many biological functions due to their ability to signal through a 
unique network of complex receptors (table 1.4; figure 1.5). IL-4 can signal through 
the type I IL-4 receptor (heterodimer of IL-4 Ra and common y (ye) chains) and the type 
II IL-4 receptor (heterodimer of IL-4Ra and IL-13 receptor a 1 (IL-13Ral) chains), but 
IL-13 only signals through the type II IL-4 receptor [Tabata et al. , 2007; Wills-Karp and 
Finkelman, 2008]. IL-4 and IL-13 cytokine responses can be completely abrogated on 
cells lacking IL-4 Ra expression as it is a component of both type I and type II IL-4 
receptors [Ban1er et al. , 1998; Mohrs et al. , 1999]. IL-13Ra2 binds with higher affinity 
to IL-13 than IL-13Ral , but appears to inhibit IL-13 ,signaling [Kawakami et al. , 2001; 
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Table 1.4. Common biological effects of IL-4 and IL-13. 
Biological effect 
j MHC-II and low affinity IgE receptor expression on B cells 
i mammary cell development 
i clearance of nematode infections 
i pulmonary fibrosis 
t CD8+ T cell avidity . 
i eosinophilia, neutrophilia and mucus secretion in 
w [Defrance et al. , 1987; Punnonen et al. , 1993] 
1; [Khaled et al. , 2007] 
n [Urban et al. , 1991; Urban et al. , 1998] 
a [Rankin et al. , 1996; Zhu et al. , 1999] 
v [Ranasinghe et al. , 2009] 
asthma 
A [Grtinig et al. , 1998; Wills-Karp et al. , 1998; Tomkinson et al. , 2001]. 
i indicates up-regulation or enhancement of the indicated effect(s) 
! indicates down-regulation or dampening of the indicated effect(s) 
Reference 
co 
~ 
Jt 
CT 
u 
A 
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Q IL-4 Q IL-13 
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Figure 1.5. IL-4/IL-13 receptor complex. IL-4 can signal through type I (heterodimer 
of IL-4Ra and ye) or type II (heterodimer of IL-4Ra and IL-13Ral) IL-4 receptors. IL-
13 can only signal through the type II IL-4 receptor. Signaling through these 
cytokines/receptors usually leads to activation of ST AT6, which translocates into the 
nucleus to activate transcription of IL-4/IL-13 responsive genes. IL-4 can also bind to 
sIL-4Ra or IL-13 can bind to IL-13Ra2 or IL-13Ra2~10, which is thought to not result 
in signaling. Hence, sIL-4Ra and IL-13Ra2 are referred to as decoy/inhibitors of IL-
4/IL-13 signaling. 
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Sivaprasad et al., 2010]. This decoy/inhibitory receptor can be membrane associated or 
soluble (IL-13Ra2~10) (figure 1.5). Similarly, a soluble form of IL-4Ra (sIL-4Ra) has 
been shown to inhibit the biological effects of IL-4 [Mosley et al. , 1989; Gessner et al. , 
1994; Borish et al., 2001]. IL-4 and IL-13 cellular signaling via the type I or type II IL-
4 receptors mainly leads to activation of STAT6 although, activation of STATl , STAT3 
and ST ATS has also been reported [Hou et al., 1994; Takeda et al. , 1996; Acacia de Sa 
Pinheiro et al., 2007]. Following activation, STAT6 translocates into the nucleus to 
activate transcription of genes (e.g. C023, MHC-II and IL-4Ra) [Nelms, 1999]. 
As described previously, our laboratory has identified that cog+ T cell avidity can be 
influenced based on the route of vaccine delivery or the presence of IL-4 and IL-13 
during vaccination of wild-type (WT) and gene knockout mice ( table 1.5). As shown in 
table 1.5 (model 11) following HIV-1 recombinant pox viral prime-boost vaccination, 
the avidity of HIV (KdGag197_205)-specific cog+ T cells inversely correlated with their 
IL-4 and IL-13 production capacity [Ranasinghe et al., 2007]. Enhancement in avidity 
in these studies favoured mucosal prime-boost vaccination regimens in the following 
manner: i.n./i.n. > i.n./i.m. > i.m./i.m .. Ranasinghe et al [2009; 2013] then established 
that IL-4 and IL-13 dampen the avidity of HIV-specific C08+ T cells, which led to 
development of novel IL-13Ra2~10 adjuvanted recombinant pox viral vaccines (table 
1.5 (model I and III)). These novel vaccines as hypothesized enhanced protection and 
Gag-specific cog+ T cell avidity following vaccination [Ranasinghe et al. , 2013]. 
Overall, our laboratory has established that mucosal HIV -1 recombinant pox viral 
prime-boost vaccination likely through reduced induction of IL-4 and IL-13 can 
enhance the avidity of HIV-specific cog+ T cells. 
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f .d. l . Table 1.5. Prime-boost models o av1 1ty regu at1on 1n our laboratory. 
Model Prime-boost Vaccines used Mouse 
vaccination genotype 
. 
regimen 
* i.n./i.m. FPV-HIV NV-HIV IL-13 -i -I 
i.n./i.m. FPV-HIVNV-HIV IL-4 -i -
i.n./i.m. FPV-HIV NV-HIV STAT6 _1_ 
i.n./i.m. FPV-HIVNV-HIV WT 
n1P i.n./i.n. FPV-HIVNV-HIV WT 
-i.n./i.m. FPV-HIV NV-HIV WT 
i.m./i.m. FPV-HIVNV-HIV WT 
III~ i.n./i.m. FPV-HIV-IL-13Ra2~ 10/ WT 
VV-HIV-IL-13Ra2~10 
i.n./i.m. FPV-HIVNV-HIV WT 
+ is a relative incremental indicator of avidity (i.e. more '+' = higher avidity) 
* [Ranasinghe et al. , 2009] 
1V [Ranasinghe et al., 2007] 
~ [Ranasinghe et al., 201 3] 
HIV-sp·ecific 
CDS+ T cell 
avidity 
+++++ 
+++++ 
++++ 
+++ 
+++++ 
+++ 
++ 
+++++ 
+++ 
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1.9 FTA assay for measuring CD8+ T cell avidity in vivo 
Various in vitro based methods are commonly used to measure various aspects of CD8+ 
T cell avidity (table 1.6). Surface plasmon resonance and pMHC-I tetramer 
staining/dissociation assays are sensitive assays that can be used to define the affinity of 
the TCR or the overall avidity of TCR and CD8 co-receptors of a CD8+ T cell clone of 
interest (table 1.6). Tetramer technology is also extremely advantageous to further 
scrutinize the avidity profiles of antigen-specific CD8+ T cells of interest. In fact, a few 
studies have used this technology to examine expression levels of various markers that 
can regulate avidity and the TCR signatures ( clonotypes) of high and low avidity 
antigen-specific CD8+ T cells of interest [Kedzierska et al. , 2005; La Gruta et al. , 2006]. 
However, the major shortcoming of surface plasmon resonance and tetramer 
technologies are that they need to be complemented with assays that provide direct 
information regarding the effector functions of CD8+ T cells. Defining avidity profiles 
based on the effector function capacity/sensitivity of CD8+ T cells to the availability of 
co-receptor molecules (i.e. CD8) or titrated amounts of peptide pulsed target cells have 
classically been described using 51 Cr release, enzyme-linked immunospot (ELISPOT) 
and intracellular cytokine staining (ICS) assays [Alexander-Miller et al. , 1996; Slifka 
and Whitton, 2001; Draenert et al., 2004]. These assays provide direct evidence 
regarding the functional avidity of CD8+ T cells, but they are usually performed in vitro. 
Ideally, avidity is best measured in vivo and will not require any in vitro manipulation 
of CD8+ T cells. Previously developed in vivo CD8+ T cell killing assays [Oehen et al. , 
1997; Barchet et al., 2000] are only able to measure the magnitude of the killing 
response in a single animal without providing any detailed measurements on functional 
avidity and epitope variant cross-reactivity in a single host animal. These limitations are 
significant obstacles for vaccine strategies that aim to induce high avidity CD8+ T cells 
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Table 1.6. Common in vitro methods used to determine COS+ T cell avidity fates. 
Method Aspects of COS+ T cell avidity measured References 
Surface •!• Technique used to determine the affinity between one b 
Plasmon TCR and one pMHC-I in real-time based on ligand 
resonance binding to surf ace immobilized receptors 
pMHC-I •!• Flow cytometry based assay used to infer avidity of <p 
tetramer multiple TCRs and CDS co-receptors to cognate 
staining and pMHC-I based on the ability of CDS+ T cells to interact 
dissociation with fluorochrome conjugated tetramerized pMHC-I 
CDS 
blocking 
Marker 
. 
expression 
analysis 
Peptide 
pulsing 
•!• Flow cytometry based cell sorting of tetramer bound 
CDS+ T cells can be used to characterize TCR chains 
( clonotypes) that characterize high and low avidity cells 
•!• Anti-CDS antibodies or CDS null tetramers are used to A 
block CDS co-receptor involvement in cognate pMHC-I 
recognition and effector functions 
•!• Flow cytometry based measurements made to determine 8 
the expression levels of various candidate markers that 
correlate with CDS+ T cell avidity 
•!• Using ELISPOT, ICS or 51 Cr release assays, the ability € 
to respond (e.g. kill or produce IFN-y) against various 
target cells pulsed with titrated amounts of cognate 
antigens (peptides) can be used to determine the antigen 
sensitivity ( overall functional avidity) of CDS+ T cells 
c [Holler et al., 2001 ; Stone et al., 2009] 
cp [Kedzierska et al., 2005; La Gruta et al., 2006] 
A [Wooldridge et al. , 2003; Choi et al., 2003] 
8 [Slifka and Whitton, 2001; La Gruta et al. , 2006] 
€ [Alexander-Miller et al., 1996; Slifka and Whitton, 2001; Draenert et al., 2004] 
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in vivo. However, a novel FTA technology has been recently developed and can be 
used to overcome these limitations [Quah et al. , 2012; Quah et al. , 2013]. The FTA 
comprises of lymphocyte target cells with unique fluorescent signatures (>200) based 
on labeling cells with a combination of carboxyfluorescein succinimidyl ester (CFSE), 
cell trace violet (CTV) and cell proliferation dye eFluor®670 (CPD) [Quah et al. , 2012; 
Quah et al., 2013]. The FT A can then be pulsed with various titrated concentrations of 
MHC-I and MHC-II binding peptides and injected into HIV-1 vaccinated mice to 
evaluate TH cell responses and CD8+ T cell avidity (based on killing responses) in vivo 
[Quah et al., 2012; Quah et al. , 2013]. Consequently, this assay can be used thoroughly 
evaluateavidity and epitope variant cross-reactivity of CD8+ T cells as well as TH cell 
responses in vivo in the same vaccinated animal. 
1.10 Pre-clinical models for testing putative HIV-1 vaccines 
In 1940, Howard Florey and Ernst Chain demonstrated that penicillin could be 
administered safely to protect mice against deadly Streptococci infections [Chain et al. , 
1940], which later translated to saving millions of human lives. This landmark study 
showed the enormous potential of using pre-clinical models for developing safe yet 
protective substances for use in humans. There are three major pre-clinical animal 
models used for HIV -1 vaccine development or as 'gatekeepers' for advancement of 
HIV-1 vaccines into humans: mice (including humanized mice), macaques and 
chimpanzees. Mice genomes are easy to manipulate and their immune responses are 
well characterized making them ideal models for testing the immunogenicity and 
protective mechanisms of putative HIV-1 vaccines. However, all known mice strains 
apart from humanized mice cannot be used to test the efficacy of HIV-1 vaccines given 
that HIV-1 does not infect mice. HIV-1 is only known to naturally infect humans and 
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chimpanzees [Gao et al. , 1999], which makes chimpanzees an ideal HIV-I challenge 
model. However, successful outcomes of HIV- I vaccine regimens tested in 
chimpanzees have not been translated in human clinical trials [Bailey, 2008]. This has 
pushed researchers to use macaques and humanized mice models to determine the 
protective potential of HIV- I vaccines [Mosier, 1996; Shedlock et al., 2009]. Macaques 
are a natural host of SIV and humanized mice can be infected with HIV -1 given that 
they are engrafted with human peripheral blood mononuclear cells. However, HIV-I 
transmission in humanized mice does not occur and the protective effects associated 
with the use of SIV vaccines in macaques so far have also not been translated in human 
clinical trials [Buchbinder et al. , 2008; Van Duyne et al., 2009]. Macaques and 
humanized mice are also difficult to maintain/access and are expensive to use. 
The reasons for the poor translational potential of putative HIV-I vaccines tested in pre-
clinical animals models is not clear, but it is probably not exclusively due to the 
challenge model chosen. It is very likely due to a significant lack in understanding of 
vaccine induced protective immune mechanisms in animals and whether induction of 
these protective responses is feasible in humans following vaccination [Shapiro, 2013]. 
Resolving these issues will help researchers understand the validity of the animal 
models chosen for developing efficacious HIV- I vaccines for use in humans. 
1.11 Basis and scope of this PhD thesis 
The PhD research project predominantly aimed towards understanding how IL-4 and 
IL-13 regulate anti-viral CD8+ T cell avidity/quality following virus infection ( chapter 
3) and HIV-I recombinant pox-viral prime-boost vaccination (chapter 4). The ability of 
FTA assays to screen for effective HIV-I recombinant pox viral prime-boost 
vaccination regimens that generated high quality T cell responses in vivo were also 
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examined ( chapter 5). Overall, the data generated from these studies provided more 
insights as to how CD8+ T cell avidity can be regulated following virus infection and 
HIV-I recombinant pox viral prime-boost vaccination. The rationales for each of these 
studies are outlined below: 
1. Cytokines require receptors to mediate signaling and no studies have evaluated how 
cytokine receptors for IL-4 and IL-13 are regulated following pox virus infection. 
Therefore, in the first study ( chapter 3) it was investigated how receptors for IL-4 
and IL-13 are regulated on immune cells following predominantly pox virus 
infections and whether regulation of these receptors influenced the avidity of anti-
viral CD8+ T cells. 
2. In the second study ( chapter 4), how cytokines IL-4 and IL-13 act on anti-viral 
CD8+ T cells to regulate avidity was investigated using a range of HIV -1 
recombinant pox viral prime-boost vaccination strategies (table 1.5). For this 
purpose, whether differential regulation of avidity molecules (i.e. lck, CD8af3, TCR, 
lck, CD 11 a and CD2) played a role in modulating HIV-specific CD8+ T cell avidity 
and polyfunctionality was investigated. 
3. Current assays that measure avidity of CD8+ T cells following HIV- I vaccination 
are usually performed in vitro, which can limit the interpretation of the effectiveness 
of vaccines in inducing high quality (i.e. avidity) T cell responses in vivo. Therefore, 
in the final study ( chapter 5) the utility of a novel FTA assay (section 1.9) to 
determine the efficacy of vaccine vectors and routes of vaccine delivery for the 
induction of high avidity and epitope variant cross-reactive CD8+ T cells as well as 
TH cell responses in vivo was evaluated. 
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Chapter 2 
Materials and Methods 
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2.1 Mice 
Pathogen-free 6-10 weeks old WT, IL-4 -/-, IL-13 -/-, STAT6 -/- BALB/c mice were bred 
and maintained under The ANU Animal Experimentation and Ethics Committee 
(AEEC) guidelines. C57BL/6, C57BL/6 IFN-y -i-, C57BL/6.SJL (CD45.1) and TCR 
transgenic C57BL/6 OT-I (CD45.2) mice were all purchased from the Australian 
Phenomics Facility, ANU. 
2.2 Ethics statement 
All animals were maintained and experiments were performed in accordance with The 
Australian National Health and Medical Research Council guidelines within The 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
All animals were also maintained in accordance with guidelines approved by AEEC, 
protocol numbers JIG 74.09 and A2011/018. Animals used for experimentation were 
monitored daily and infected mice were scored for signs of illness and weight loss. 
Animals were ethically sacrificed using cervical dislocation in accordance with the 
above AEEC approved protocols. 
2.3 Peptide and tetramer synthesis 
All peptides and tetramers used in this study were synthesized at The BRF, JCSMR. 
Peptides included the MHC-I-binding peptides, SPYAAGYDL (F2L, immunodominant 
VV epitope L dF226-34), KYGRLFNEI (A52R, subdominant VV epitope KdA5275_83), 
SPGAAGYDL (F2L mut, a MV A epitope homologous to F2L), AMQMLKETI (HIV 
Gag, Gag epitope KdGag191-2os), AMQMLKDTI (HIV Gag mut, HIV Gag subtype C 
variant [Earl et al., 2009]), AMQMLEKTI (HIV neg), VGPTPVNII (HIV Pol, Kd-
restricted HIV Pol epitope [Wild et al., 2009]), RGPGRAFVTI (HIV Env, Kd-restricted 
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HIV Env epitope [Takeshita et al. , 1995], and the MHC-II-binding peptide 
PVGEIYKRWIILGLN (Gag TH, H-2d-restricted HIV Gag epitope [Mata and Paterson,-
1999]). Tetramers used in this study include allophycocyanin conjugated KdGag197_205 
or Kd A521s-83 tetramers. 
2.4 Viruses 
MV A, a virulent Semliki Forest virus ( aSFV), FPV, recombinant VV encoding the 
ovalbumin peptide SIINFEKL (VV-OVA2s1-264) or A/PRS (HlNl) influenza virus 
stocks used in this study were gifts from Associate Professor Guna Karupiah, Dr. 
Mohammed Alsharifi, Dr. David Boyle, Dr. David Tscharke and Dr. Y oichi Furuya, 
respectively. All FPV and MV A stocks were grown and titrated in chick embryonic 
epithelial cells. aSFV stocks were grown and titrated in BHK cells. A/PRS influenza 
virus stocks were prepared as described in Alsharifi et al [2009]. Briefly, one 
hemmagglutinin unit of virus in 100 µl of saline was injected into 10-days old 
embryonated chicken eggs, incubated for 48 hours at 3 7 °C, and then stored at 4 °C 
overnight. Subsequently, the allantoic fluids fro1n these eggs were then harvested and 
the virus purified using hemagglutinin based binding of chicken red blood cells. The 
purified virus was titrated using Madin-Darby canine kidney cells to determine the virus 
stock concentration. VV Western Reserve (VV-WR) strain and recombinant VV stocks 
were grown and titrated in 143B cells. Recombinant VV encoding murine IL-4 and 
hemagglutinin (VV-HA-IL-4) and the VV encoding hemagglutinin (VV-HA) were 
prepared as described in Sharma et al [1996]. These stocks were kindly provided by 
Professor Alistair Ramsay. The reco1nbinant FPV encoding HIV-1 AE clade Gag, Pol 
and Env (FPV-HIV; FPV117a) and recon1binant VV encoding HIV-1 AE clade Gag 
and Pol (VV-HIV; VV336) used in the current study were exactly as those used 
, 
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previously in Ranasinghe et al [2006]. Recombinant VV encoding HIV AE clade Env 
(VV337) was prepared as described in Coupar et al [2006]. Recombinant FPV-HIV 
and VV-HIV encoding the murine IL-13Ra2~10 (IL-13 inhibitor vaccines) were 
constructed exactly as describe in Ranasinghe et al [2013]. 
2.5 Liposome preparation 
Jason Price at Lipotek kindly synthesized the liposome constructs used in this project 
and the liposome construction process is briefly described here. Liposome doses were 
encapsulated with a 35 mg bolus of HIV Gag mut peptide and a 1 mg bolus of LPS. 
Liposomes were formed by suspending a desiccated thin film of lipids composed of 
DOPC:DOPG:DSPE-PEG750:D0PE:cholesterol (Avanti Polar Lipids) at a w:w ratio of 
10:4:2: 1:2 respectively, in water. HIV Gag mut and LPS were incorporated into the 
liposomes by vortexing for 30 seconds, freezing on dry ice and lyophilisation, before 
stepwise rehydration in water. Liposomes were then sized by sequential extrusion 
through 0.4 mm, 0.2 mm and 0.1 mm PC membranes using a Northern Lipids 'Lipex' 
extruder with a 10 ml thermobarrel warmed to 50 °C. Unencapsulated peptide was 
removed by dialysis using 300 kDa MWCO tubing (Spectrapore). Peptide content of the 
liposomes was analyzed by RP-HPLC (Waters HPLC system) and concentration 
determined by comparison with peptide standards. The Prepared liposomes were then 
administered intravenously (i.v.) in a 200 µl bolus. 
2.6 Virus infection and HIV-1 prime-boost vaccination 
All virus infections in age- and sex-matched mice were conducted intraperitoneally 
(i.p.) at a dose of 3 x 106 plaque forming units (PFU)/mouse or 5 x 106 PFU/mouse for a 
period of 7 days unless otherwise stated. 
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For all HIV-1 prime-boost vaccinations except where indicated, pathogen free 6-10 
weeks old BALB/c mice were primed i.n. with 1 x 107 PFU of FPV-HIV (FPV117a) 
followed by i.m. booster vaccination with 1 x 10 7 PFU of VV-HIV (VV3 3 6) 14 days 
apart as described in Coupar et al [2006] and Ranasinghe et al [2006]. In chapter 5, VV-
HIV immunizations were done using i.n. or i.m. routes with a mixture of 2.5 x 106 PFU 
of VV336 and 2.5 x 106 PFU of VV337 in an attempt to generate Env-specific T cell 
responses. T cell responses were evaluated 7 or 14 days post booster vaccination. 
2. 7 Adoptive cell transfer of OT -I cells 
Red blood cell (RBC)-depleted splenocytes from 8 weeks old C57BL/6 OT-I mice were 
injected i.v. (10 x 106 cells in 200 µl of phosphate buffer saline (PBS)) into a lateral tail 
vein of 8 weeks old recipient C57BL/6.SJL mice. Subsequently, the recipient mice were 
rested ove1night (12-18 hours) and infected i.p. with 5 x 106 PFU/mouse of VV-WR 
control or VV-OV A2s7-264 · 
2.8 Flow cytometry 
2. 8.1 Antibodies 
The following monoclonal antibodies against mouse antigens and the respective isotype 
controls for CD8a, CD4, CD45R (B220), CD124 (IL-4Ra), CD132 (ye), CD49b 
(DX5), CD44, CD69, CD25 , CD45.1 , CD62L, CD1 lc and TNF-a were all obtained 
from Becton Dickinson (BD) Biosciences, USA. Monoclonal antibodies against mouse 
granzyme B (GzmB), CD45.2, CD2, CD1 la, TCR~, IFN-y, H-2Kct and CD8~.2 (clone 
53-5.8) and I-Ad were obtained from BioLegend, USA. Monoclonal antibodies against 
mouse CD213a (IL-13Ral ) and IL-2 were obtained from eBioscience, USA. These 
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antibodies were used as purified, fluorescein isothiocyanate, phycoerythrin, peridinin 
chlorophyll protein, pacific blue, alexa fluor 700, horizon V500, brilliant violet 605, 
PE-cyanine, allophycocyanin or allophycocyanin-eFluor 780 conjugates. Secondary 
fluorescein isothiocyanate conjugated anti-goat IgG (Jackson ImmunoResearch) was 
used to detect purified polyclonal goat IgG anti-mouse IL-13Ra2 (R&D systems) 
binding to splenocytes. Cell viability was assessed with the dye Hoechst 33258 (1 
mg/ml, Calbiochem-Behring Corp.) as described in Quah et al [2004]. 
2. 8. 2 Cell surface and intracellular staining procedures 
In all flow cytometry-based studies REC-depleted splenocytes were used. Cell surface 
staining and intracellular staining were performed using the respective methods 
described in Ranasinghe et al [2006]. Briefly, for cell surface staining 1-4 x 106 cells 
were incubated 30 minutes at 4 °C in the presence of purified or fluorochrome 
conjugated antibodies diluted in PBS containing 1 % foetal calf serum (PCS). 
Subsequently, samples were washed twice using PBS containing 1 o/o PCS, fixed in 
0.5% paraformaldehyde, prior to flow cytometry analysis. 
In all the experiments described here, intracellular GzmB staining of cell surface 
stained samples was conducted using freshly isolated REC-depleted splenocytes that 
were not stimulated with peptides. For IFN-y, TNF-a and IL-2 ICS, 1-4 x 106 cells in 
200 µl of Roswell Park Memorial Institute (RPMI) culture medium (Invitrogen, 
Australia) containing 10% PCS were seeded in 96 well U-bottom plates (BD 
Biosciences) in the presence or absence of 0.1 µg/ml of KdA5275_83 , L dF226_34 or 
KdGag197-2os peptides. When CD8 blocking was performed, cells were incubated with 1 
µg/ml of purified anti-mouse CD8~.2 prior to and during KdGag197_205 peptide 
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stimulation. Subsequently, peptide stimulated or unstimulated cultures were left for 1 
hour at 37 °C + 5% CO2 prior to addition of lx Brefeldin A (eBioscience, USA). The 
cultures were then left for further 4 hours at 3 7 °C + 5% CO2 prior to conducting cell 
surface staining as described before. 
For intracellular staining, cell surface stained samples were fixed and permeabilized 
using commercial intracellular fixation and permeabilization buffers according to the 
manufacturer' s protocol ( eBioscience, USA). Subsequently, permeabilized cells were 
incubated for 30 minutes at 4 °C in the presence of purified or fluorochrome conjugated 
antibodies diluted in lx permeabilization buffer ( eBioscience, USA). Intracellular 
stained sa1nples were washed twice using PBS containing 1 % FCS, fixed in 0.5o/o 
paraformaldehyde prior to flow cytometry analysis. All cell surface and intracellular 
stained samples were analyzed using fluorescence activated cell sorting (FACS) Calibur 
(BD Biosciences, USA) or BD LSR II (BD Biosciences, USA) flow cytometry 
machine. For each sample 2 x 105 - 1 x 106 events were acquired. Flow cytometry plots 
of the analyzed data were constructed using the FlowJo Tree Star software (version 
8.7.1). 
2.9 Tetramer staining and dissociation assays 
Tetramer staining was done using REC-depleted splenocytes from vaccinated mice as 
described in Ranasinghe et al [2007]. For blocking CD8 engagement with KdGag 197_205 
tetramer, cells (2 x 106 cells/25 µl PBS) were incubated with varying concentrations of 
purified anti-mouse CD8~.2 for 30 minutes at 4 °C prior to tetramer staining. When 
tetramer dissociation was performed, tetramer stained cells were incubated for 60 
minutes at 37 °C + 5% CO2 in the presence of 25 µg/ml of anti-mouse H-2Kd (2 x 106 
cells/40 µl PBS) to prevent tetramer re-binding to .cells. After tetramer staining and/or 
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dissociation, cells were washed twice using PBS + 1 % FCS prior to conducting a cell 
surf ace stain. 
2.10 FTA preparation 
FT A was constructed by labeling spleen cells with combinations of the dyes CFSE, 
CTV and CPD as described previously [Quah et al., 2012]. Briefly, splenocytes 
supplemented with RPMI + 10% FCS at 20 °C, were labeled with 0-66000 nM of each 
dye in 1-2 ml aliquots for 5 minutes and then washed at least three times. For FTA 
constructs, aliquots of splenocytes from BALB/c WT mice were initially labeled with 
several concentrations of CTV. Cells were then split equally and labeled with several 
concentrations of CFSE, washed once and then incubated with MHC-I and MHC-II 
binding peptides for 1 hour at 3 7 °C. Cells were then washed through a FCS cushion 
and subsequently washed twice more. Replicate samples were then labeled with CPD. 
After washing the cell samples twice, all aliquots were pooled and washed again and 
then labeled with 14 mM dialkylcarbocyanine lipophilic tracer dye (Dil) from 
Invitrogen. The FTA was then resuspended at up to 25 x 1 o? cells/ml for injection into 
mice. 5 x 10 7 of prepared FTA target cells were injected into a mouse and left in vivo 
for 18 hours prior to assaying for FT A target cell help and killing. 
2.11 In vitro anti-TCR stimulation of splenocytes 
Splenocytes from nai've BALB/c mice were cell surface stained using fluorochrome 
conjugated antibodies against mouse CD44 and CD8a for purification of CD4410 CD8+ 
splenocytes using the F ACSAria II (BD Biosciences). 2 x 104 of F ACS sorted CD4410 
CD8+ splenocytes in 100 µl of RPMI + 10% FCS were then cultured in U-bottom well 
plates coated with 3 µg/ml of anti-CD3r or PBS (mock) in the presence or absence of 
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0.1 ng/ml of recombinant murine IL-4 (R&D systems). Prior to seeding of cells, 96 well 
U-bottom plates were coated with 3 µg/ml of purified mouse anti-CD3£ (BioLegend) or 
PBS (3 0 µI /well) for 18 hours at 4 °C and washed three times with PBS (200 µI/well). 
The plates containing F ACS purified cells were then incubated for further 8 hours at 3 7 
°C + 5% CO2 prior to cell surface staining and flow cytometry analysis. 
2.12 Quantitative real-time polymerase chain reaction (PCR) 
IL-4Ra10 and IL-4Rahi CD8+ splenocytes (see supplementary figure 3A) from 
BALB/c mice infected with VV-WR for 7 days or total CD8+ splenocytes from 
unimmunized control BALB/c mice were sorted using F ACSAria II machine. RNA 
extracted from sorted cells was used to generate cDNA as described in Ranasinghe et al 
[2007]. Quantitative real-time PCR with specific primers (table 2.1) and Power SYBR 
Green PCR Master Mix (Applied Biosystems) were used to amplify cDNA for 40 
cycles according to the manufacturer' s guidelines of the Applied Biosystems SDS 7900 
real-time PCR machine. 
Primer melting curves were analyzed to ensure that target-specific amplification had 
occu1Ted. NCBI Primer-BLAST database was used to verify that the primers used in 
this study did not anneal to any unintended products in the mouse genome. mRNA 
encoding ribosomal protein L32 was amplified as the house keeping reference control to 
measure fold change in mRNA transcript levels (see section 2.13.3). 
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T bl 2 1 P . a e . . r1mers use dt ft f If PCR or quan I a 1ve rea - 1me . 
Primer Sense primer 5' ~ 3' Anti-sense primer 5'~3 ' 
IL-4Ra ACACTACAGGCTGATGTTCTTCG TGGACCGGCCTATTCATTTCC 
GzmB CCACTCTCGACCCTACATGG GGCCCCCAAAGTGACATTTAT 
L32 GCTGGAGGTGCTGCTGATGTG CGTTGGGATTGGTGACTCTGATGG 
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2.13 Statistical analysis 
2.13.1 Net fold reduction in IL-4Ra expression calculation 
Net fold reduction of cell surface IL-4 Ra expression was calculated using mean 
(geometric) fluorescent intensity (MFI) obtained from flow cytometry on gated CD8+ 
splenocytes from unimmunized or VV-WR infected mice as follows: ((MFI (IL-
4Ra)unimmunized - MFI (IL-4Ra)vv-WR) / MFI (IL-4Ra)unimmunizect). 
2. 13. 2 FTA statistical analysis 
The % specific killing was assessed as previously described [Quah et al. , 2012] using 
the following formula: 
% specific killing 
Targets+~ept~·de pnmed 
T t +nil arge sprimed 
= 1- ~~~~'--~~--"-~ 
Targets+p.epu~e 
naive .
1 T t +rn arge s naive 
X 100 
T cell help was assessed on the basis of CD69 up-regulation of FTA B cell by antibody 
labeling and flow cytometry. Expression of CD69 was calculated by subtracting the 
MFI (CD69) on FT A B cells from na:ive mice from that of FT A B cells from the 
vaccinated mice as previously described in Quah et al [2013]. 
Statistic values, including area under the curve (AUC = peptide (µM) x % specific 
killing response) and EC50 (peptide concentrations giving half maximal % specific 
killing) were calculated using GraphPad Prism Software. To calculate EC50 values the 
peptide concentrations in response curves were transformed to log10 (µM), specific 
killing normalized to 100% and data modeled to a si-gmoidal dose-response curve. 
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2.13. 3 Fold change in mRNA-transcript levels calculation 
The fold change in mRNA transcript levels was calculated using the 2-MCT method. 
L\L\CT was calculated as follows: ((CTtarget - CTreference) of sorted IL-4Ra10/ IL-4Rahi 
CD8+ T cells) - (CT target - CT reference) of nai've CD8+ T cells. 
2.13. 4 Statistical significance testing 
All the data presented in this study have been reproduced in at least two independent 
experiments unless otherwise stated. The data plotted in all the graphs shown except 
where indicated represent the mean and the error bars depict the standard error of the 
mean (SEM). Statistical significance of the data and the p values were calculated using 
the Graph InStat software (version 3.10). In all statistical significance analysis, a 
student's unpaired t-test, Mann-Whitney nonparametric two-tailed t-test or one-way 
ANOV A was used. 
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Chapter 3 
The Role of IL-4/IL-13 Cytokine Receptors in 
Modulating Anti-Viral CDS+ T Cell Quality 
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Please note that the data presented in this chapter have now been published in: 
Wijesundara DK, DC Tscharke, RJ Jackson and C Ranasinghe. Reduced Interleukin-4 
Receptor alpha Expression on CD8( +) T Cells Correlates with Higher Quality Anti-
Viral Immunity. PLoS One 2013; 8: e55788. 
3.1 Introduction 
Protection against intracellular pathogens ( e.g. viruses and parasites) and tumors often 
requires the activation of effector CD8+ T cells, which usually mediate cytolysis upon 
recognition of non-self pMHC-I complexes presented on the surface of malignant cells 
or virus-infected cells [Zinkemagel et al., 1974; Harty et al., 2000; Dudley et al., 2002]. 
In HIV-I infections, increased susceptibility of virus-infected CD4+ T cells to CD8+ T 
cell mediated cytolysis has been associated with superior virus control in elite 
controllers [Buzon et al., 2014]. However, a collection of CD8+ T cell effector 
functions, not exclusively cytolysis, appears to be important in controlling virus 
infections. These include the ability to mount high avidity interactions with virus-
infected cells, produce multiple anti-viral cytokines (i.e. IFN-y and TNF-a), induce a 
high clonal turnover rate, and/or the ability to produce chemoattractants ( e.g. 
macrophage inflammatory protein- I ~) to recruit immune cells to virus-infected sites 
[Derby et al. , 2001; Almeida et al. , 2007; Seder et al. , 2008]. These effector functions 
define the quality of effector CD8+ T cell responses against viruses. 
The use of IL-4 Ra -/-, IL-13 Ra 1 -/-, ye -/- and IL-13 Ra2 -/- mice have shown that these 
receptors are indeed important for controlling functions of IL-4 and IL-13 in allergic 
diseases and parasitic infections [Mohrs et al. , 1999; Sivaprasad et al., 2010, Junttila et 
al., 2008]. However, these studies provide limited insights as to how these receptors are 
regulated at a cellular level in vivo during the course of a pathogenic infection. A study 
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by Tanaka et al [2007] reported that cell surface IL-4Ra expression is down-regulated 
on activated CD4+ T cells in vivo following L. major infection. This was found to be 
due to degradation of IL-4Ra in intracellular compartments of activated CD4+ T cells in 
a TCR and dedicator of cytokinesis 2 (DOCK2) dependent manner [Tanaka et al. , 
2007]. In another study, Perona-Wright et al [2010] have also shown that cell surface 
IL-4Ra expression was down-regulated on activated CD4+ T cells following H 
polygyrus infection of mice, which was thought to render these cells refractory to 
further stimulation with IL-4. On the contrary, na:ive bystander CD4+ T cells in this 
instance were found to up-regulate IL-4Ra making them more responsive to IL-4 
[Perona-Wright et al., 201 OJ. These studies suggest that IL-4 Ra plays a critical role in 
tuning responsiveness of CD4+ T cells to IL-4 and/or IL-13 during infection with 
pathogens. 
Despite recent studies showing the importance of regulating IL-4Ra expression on 
CD4+ T cells following parasitic infection in vivo, only few studies have addressed how 
the cytokine receptors for IL-4/IL-13 are regulated on CDS+ T cells following virus 
infection in vivo. The current study initially investigated how IL-4 Ra, ye, IL-13 Ra 1 
and IL-13Ra2 were regulated on CDS+ T cells and other immune cells predominantly 
following VV infection of mice. After obtaining results showing that only IL-4Ra 
expression was differentially regulated on CDS+ T cells as a consequence of VV 
infection of mice, the current study explored the mechanisms involved in this process 
and whether differential regulation of IL-4Ra affected the quality of anti-viral CDS+ T 
cell immunity. 
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3.2 Results 
3. 2.1 Regulation of IL-4/IL-l 3 receptor components during VV infection 
To examine whether VV infection induced differential regulation of IL-4/IL-13 receptor 
subunits on immune cells known to be important for clearance of viral infections, 
splenocytes from unimmunized or VV-WR strain infected BALB/c WT mice were 
analyzed using flow cytometry during the peak (i.e. 7 days) of anti-viral immunity. Cell 
surface IL-13Ra 1, ye and intracellular IL-13Ra2 expression levels on gated B220\ 
CD4\ CD8\ DX5+ (NK cells) and CD1 lchigh 1-A\igh (DCs)) splenocytes from VV-WR 
infected mice and unimmunized mice were similar (figure 3.1). Cell surface IL-13Ra2 
expression was not detectable above background expression levels in the cell subsets 
shown in figure 3.1 (data not shown). Interestingly, cell surface IL-4Ra expression was 
up-regulated on CD1 lchigh 1-A\igh cells and down-regulated on CD4+ and CD8+ T cells 
as a consequence of VV infection (figure 3.1). Down-regulation of IL-4Ra was not 
uniformly observed on all CD4+ or CD8+ T cells following VV infection with some 
cells retaining similar IL-4Ra expression levels to that observed in unimmunized mice. 
3.2.2 Down-regulation of IL-4Ra expression correlates with the magnitude of effector 
CD8+ T cells 
To clearly understand the mechanisms responsible for mediating down-regulation of 
cell surface IL-4 Ra expression on CD8+ T cells following VV infection, the kinetics of 
down-regulation of this receptor on CD8+ T cells was monitored. Using ICS and GzmB 
expression assays, data revealed that VY-specific effector CD8+ T cells emerged on day 
5 post-infection (p.i.), peaked on day 7 p.i. and gradually declined from days 14-28 p.i. 
with VV-WR (figure 3.2A and 3.2B). Similarly, reduction in cell surface IL-4Ra 
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Figure 3.1. Distribution of IL-4Ra, ye, IL-13Ral and IL-13Ra2 on immune cells 
following VV infection. BALB/c WT mice infected for 7 days with VV-WR or 
unimmunized were sacrificed and splenocytes harvested for analysis using flow 
cytometry. The histogram plots show cell surface expression of IL-4Ra, ye, IL-13Ral 
and intracellular expression of IL-13Ra2 on gated B220\ CD4\ CD8\ DXS\ and 
CD 11 chigh I-A \igh splenocytes from a representative VV-WR infected mouse (red lines) 
and an unimmunized mouse (blue lines). The plots are representative of at least 12 mice 
tested in at least three independent experiments. 
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Figure 3.2. Reduction in IL-4Ra expression correlates with magnitude of anti-viral 
effector responses on CD8+ T cells. Unimmunized or VV-WR infected BALB/c WT 
mice were sacrificed at the indicated time points and splenocytes used for flow 
cytometry analysis or for ICS following Kd A5275_83 or -L dF226_34 in vitro peptide 
stimulation of splenocytes as described in section 2.8.2. A and B, The mean (n = 4) 
percentage of CD8+ splenocytes (A) and the total number of CD8+ splenocytes (B) from 
VV-WR infected mice that expressed GzmB or IFN-y following in vitro peptide 
stimulation. C, The kinetics of the mean (n = 4) net fold reduction in cell surface 
expression of IL-4Ra on gated CD8+ splenocytes from VV-WR infected mice relative 
to unimmunized mice. Net fold reduction was calculated using MFI values as described 
in section 2.13.1. The data shown is representative of at least two independent 
experiments and the error bars depict the SEM. 
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expression on CDS+ T cells following VV-WR infection was detected on day 5 p.i., 
peaked on day 7 p.i. (figure 3.2C). The expression of this receptor on CDS+ T cells then 
increased from days 14-28 p.i. with VV-WR (figure 3.2C). Thus, the magnitude of 
down-regulation of IL-4Ra expression on CDS+ T cells correlated with the increase in 
the magnitude of the anti-viral effector CDS+ T cell responses following VV infection. 
3.2.3 Down-regulation of IL-4Ra is TCR dependent and restricted to virus-specific 
CD8+ T cells 
Next the OT-I TCR transgenic system was used to show whether IL-4Ra down-
regulation was restricted to CDS+ T cells responding to virus. Splenocytes from OT-I 
mice (CD45.2+) were transfetTed i.v. into congenic C57BL/6.SJL (CD45.1 \ CD45.2-) 
recipient mice prior to infection of these mice with VV-OV A2s7-264 or VV-WR, which 
does not express KbOVA257_264 (SIINFEKL) epitope. CDS+ T cells from OT-I mice 
almost exclusively recognize KbOV A257_264 and so should only be primed by VV-
OV A2s7-264 and not VV-WR. This was confirmed using GzmB as a marker of activation 
(figure 3.3A). IL-4Ra levels were also measured (figure 3.3B and 3.3C), and down-
regulation of this receptor on OT-I cells (CD45.2l was only seen in mice infected with 
VV-OV A2s7-264· By contrast IL-4Ra levels were reduced on recipient (CD45.2-) CDS+ 
T cells irrespective of the strain of virus. Thus, IL-4 Ra levels were only reduced on 
activated virus-specific CDS+ T cells. 
F ACS sorted polyclonal na:ive (CD4410) CD8+ T cells were also cultured in vitro with or 
without anti-TCR stimulation to determine whether IL-4Ra down-regulation was TCR 
dependent. IL-4Ra down-regulation was observed on CDS+ T cells as a consequence of 
plate-bound anti-CD3£ stimulation suggesting that this phenomenon was also TCR 
dependent (supplementary figure 1). ., 
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3.2.4 Down-regulation of IL-4Ra is a general property of activated anti-viral CD8+ T 
cells 
To evaluate whether down-regulation of cell surface IL-4Ra expression on activated 
CD8+ T cells is specific to VV infections, IL-4 Ra expression was analyzed on effector 
(GzmB+ CD62L-) and naYve (GzmB- CD62L +) CD8+ T cells as described in Yuen et al 
[2010] following infection of BALB/c WT mice with VV-WR, MVA, aSFV, FPV or 
A/PR8 influenza virus (figure 3.4A). Cell surface IL-4Ra expression on effector CD8+ 
T cells compared to naYve bystander CD8+ T cells was significantly lower in all the 
mice infected with the different viruses (figure 3.4B and 3.4C). There were no 
significant differences between the levels of cell surface IL-4 Ra expression on effector 
or naYve CD8+ T cells that developed following VV-WR infection and other viral 
infections (figure 3.48 and 3.4C). Therefore, down-regulation of cell surface IL-4Ra 
expression on activated CD8+ T cells is a general feature of virus infections in vivo. 
3.2.5 Importance of IL-4, IL-13, IFN-y and STAT6 in regulating IL-4Ra expression on 
CD8+ T cells following virus infection 
IL-4, IL-13 and IFN-y are cytokines that play a role in regulating IL-4 Ra expression on 
cells [Serpier et al., 1997; Wills-Karp and Finkelman, 2008]. Thus, it was next 
determined whether down-regulation of cell surface IL-4Ra expression on anti-viral 
effector CD8+ T cells was dependent on IL-4, IL-13, STAT6 or IFN-y. For this purpose, 
IL-4Ra expression was analyzed on effector (GzmB+ CD62L-) and naYve (GzmB-
CD62L +) CD8+ T cells from relevant gene knockout and littermate WT control mice 
infected with VV-WR. Cell surface IL-4 Ra expression on naYve CD8+ T cells, but not 
effector CD8+ T cells was significantly lower in IL-4 -1-, IL-13 -/- and STAT6 -/- BALB/c 
mice compared to BALB/c WT control mice (figure 3.5A and 3.5B). Interestingly, 
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Figure 3.3. Cell surface down-regulation of IL-4Ra specifically occurs on activated 
CDS+ T cells. Na'.ive C57BL/6.SJL (CD45.1 \ CD45.2-) mice that received 10 x 106 
C57BL/6 OT-I splenocytes (CD45.2+) i.v. were kept unimmunized or infected i.p. with 
5 x 106 PFU of VV-WR or VV-OV A257_264 for 7 days prior to sacrifice and flow 
cytometry analysis. A, Representative contour plots showing cell surface CD45 .2 and 
intracellular GzmB expression on gated CDS+ splenocytes from a recipient mouse of the 
indicated group. B, Representative histogram plots showing cell surface IL-4Ra 
expression on gated CDS+ CD45 .2- (left column of plots) or CDS+ CD45 .2+ (right 
column of plots) splenocytes from a recipient mouse kept unimmunized, infected with 
VV-WR or VV-OV A2s7-264· C, MFI (n = 6) representing cell surface IL-4Ra expression 
on gated CDS+ CD45 .2- or CDS+ CD45 .2+ splenocytes from recipient mice of the 
indicated group. One-way ANOVA (Tukey's Multiple Comparison) was used for 
testing significance of the data(*** - p < 0.001). Similar results have been obtained in 
three independent experiments and the error bars depict the SEM. 
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Figure 3.4. Down-regulation of IL-4Ra is a general feature of activated CD8+ T 
cells following virus infection. BALB/c WT mice were infected i.p. with 3 x 106 PFU 
of the indicated viruses or kept unimmunized for 7 days prior to sacrifice and flow 
cytometry analysis . A, Dot plots showing cell surface CD62L expression and 
intracellular GzmB expression on gated CDS+ splenocytes from a representative mouse 
of the indicated group. B, Representative histogram plots showing cell surface IL-4Ra 
expression on the indicated CDS+ splenocyte subset from a representative mouse 
infected with the indicated virus. C, MFI (n = 5) representing cell surface IL-4Ra 
expression on the indicated splenocyte subset from nnce infected with the indicated 
viruses. Similar results have been obtained in three independent experiments and the 
error bars shown depict the SEM. 
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Figure 3.5. IL-4, IL-13 and ST AT6 regulate IL-4Ra expression on CD8+ T cells 
following VV-WR infection. Gene knockout mice and respective littermate WT 
control mice were infected with VV -WR for 7 days or kept unimmunized prior to 
sacrifice and analysis using flow cytometry. A, Representative histogram plots showing 
cell surface IL-4Ra expression on the indicated CD8+ splenocyte subset from a gene 
knockout mouse or a littermate WT control mouse. B, MFI (n = 5) representing cell 
surface IL-4 Ra expression on the indicated CD8+ splenocyte subset from mice of the 
indicated genetic background infected with VV-WR. C, Representative histogram plots 
showing cell surface IL-4 Ra expression on the indicated CD8+ splenocyte subset from 
an unimmunized mouse or VV -WR infected mouse belonging to the indicated genetic 
background. All the results shown are representative of at least two independent 
experiments. Error bars when shown depict the SEM and one-way ANOVA (Dunnett 
Multiple Comparison) was used to determine the statistical significance of the data 
relative to WT control mice(*** - p < 0.001). 
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na:ive B cells, CD4 + T cells, NK cells and DCs did not express lower levels of IL-4 Ra 
in na:ive gene knockout mice for IL-4, IL-13 and ST A T6 relative to WT controls 
(supplementary figure 2). 
In these experiments, IL-4Ra expression levels on na:ive CD8+ T cells from VV-WR 
infected mice and unimmunized mice were also measured. This was done to investigate 
the possibility that VV-WR infection induced IL-4 and/or IL-13 to up-regulate IL-4Ra 
expression on na:ive bystander CD8+ T cells similar to what has been reported on na:ive 
bystander CD4+ T cells responding to IL-4 following parasitic infection [Perona-Wright 
et al., 2010]. However, na:ive CD8+ T cells from VV-WR infected IL-13 -/-, IL-4 -/-, 
STAT6 -!- or WT control BALB/c mice expressed similar levels of cell surface IL-4Ra 
to that of na:ive CD8+ T cells from unimmunized mice belonging to the respective 
genetic background (figure 3.SC). This suggests that VV-WR infection was not 
inducing significant levels of IL-4 and/or IL-13 to up-regulate IL-4Ra expression on 
na:ive CD8+ T cells. In contrast to the knockout mice described above, no difference in 
IL-4Ra expression levels were seen on any CD8+ T cells from C57BL/6 IFN-y -/-
compared to C57BL/6 WT controls (figure 3.5A and 3.5B). Collectively, data suggest 
that IL-4, IL-13 and STAT6 are required for maintaining high levels of IL-4Ra 
expression on na:ive CD8+ T cells. 
..L 
3.2. 6 Increased IL-4 during virus infection induces higher levels of IL-4Ra on CD8 · T 
cells 
Next whether IL-4Ra levels on CD8+ T cells were fixed/unchanged, or responsive to 
IL-4 during infection was investigated. For these studies, VV-HA-IL-4 and the control 
VV-HA were used for infection. Strikingly, IL-4Ra expression was higher in BALB/c 
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WT mice infected with VV-HA-IL-4 relative to VV-HA infection when comparing 
naYve (GzmB- CD62L +) or effector (GzmB+ CD62L-) CD8+ T cells (figure 3.6). 
Similarly, up-regulation ofIL-4Ra was also observed following IL-4 exposure ofFACS 
sorted naYve CD8+ splenocytes from BALB/c WT mice in vitro stimulated or 
unstimulated with plate-bound anti-CD3r (supplementary figure 1). When the VV-HA 
and VV-HA-IL-4 infection experiments were performed using BALB/c STAT6 -/- mice, 
no difference in IL-4Ra expression was observed on CD8+ T cells unlike that observed 
in BALB/c WT mice (figure 3.6). Data indicate that the amount of IL-4 available 
during virus infection can regulate the expression of IL-4 Ra on CD8+ T cells in a 
STAT6 dependent manner. 
3.2. 7 Transcriptional control is not predictive of protein IL-4Ra expression on effector 
CD8+ T cells following VV-WR infection 
Whether lower production of IL-4Ra mRNA transcripts was responsible for down-
regulating protein expression of IL-4 Ra on CD8+ T cells following VV infection was 
-
also evaluated. RNA extracted from FACS sorted IL-4Ra10 and IL-4Rahi CD8+ T cells 
(as shown in supplementary figure 3A) were used in these studies to synthesize cDNA 
for a quantitative real-time PCR analysis as described in section 2.12. The data indicate 
that there were no significant differences in the IL-4Ra mRNA transcript levels 
between IL-4Ra10 and IL-4Rahi CD8+ T cells despite the differences in IL-4Ra protein 
expression between these two cell populations (supplementary figure 3B). GzmB 
mRNA transcript levels were measured as a positive control given that GzmB mRNA 
transcript levels have been reported to be enhanced on VY-specific effector/memory 
CD8+ T cells compared to naYve CD8+ T cells [Yoshida et al., 2006]. Data showed that 
IL-4Ra10 CD8+ T cells clearly expressed much higher (-50 fold) GzmB mRNA 
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Figure 3.6. IL-4Ra is up-regulated on CD8+ T cells in a STAT6 dependent manner 
following VV-HA-IL-4 infection. WT or STAT6 -!- BALB/c mice were infected with 5 
x 106 PFU of VV-HA control, VV-HA-IL-4 or kept unimmunized for 7 days prior to 
sacrifice and analysis using flow cytometry. A and B, Representative histogram plots 
showing cell surface IL-4Ra expression (A) and the MFI (n = 5) of cell surface IL-4Ra 
expression (B) on the indicated CD8+ splenocyte subset from infected mice of the 
indicated genetic background. The data shown is representative of two independent 
experiments and the error bars depict the SEM. One-way ANOV A (Dunnett's Multiple 
Comparison) was used to determine the statistical significance of the data relative to 
respective cell subset from VV-HA infected mice(*** - p < 0.001). 
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transcript levels compared to IL-4Rahi CD8+ T cells (supplementary figure 3B). 
3.2.8 IL-4 and IL-13 regulate the establishment of IFN-y+ TNF-a+ producing effector 
CD8+ T cells following virus infection 
High avidity virus-specific CD8+ T cells express elevated levels of both IFN-y and 
TNF-a [La Gruta et al., 2006; Ranasinghe et al., 2007]. To evaluate whether 
differential regulation of cell surface IL-4 Ra expression on CD8+ T cells may play a 
role in regulating CD8+ T cell functional quality, IFN-y and TNF-a production were 
measured using ICS following in vitro KdA5275_83 or LdF226-34 peptide stimulation of 
splenocytes from VV infected WT and gene knockout BALB/c mice. Amongst the gene 
knockout mice examined only BALBI c IL-4 -/- mice developed greater numbers of IFN-
y expressing Kd A5275_83 or L dF226_34 specific CD8+ T cells compared to BALB/c WT 
control mice following VV-WR infection (figure 3. 7B). However, the enhancement in 
cell numbers in this instance was not robust enough to reach statistical significance 
(figure 3. 7B). The number of IFN-y + TNF-a + Kd A5275_83 or L dF226_34 specific CD8+ T 
cells and the proportion of Kd A5275_83 or L dF226_34 specific CD8+ T cells that expressed 
TNF-a in addition to IFN-y was higher in VV-WR infected IL-13 -/-, IL-4 -/- and STAT6 
-!- BALB/c mice compared to BALB/c WT control mice (figure 3.7). Given that IL-4Ra 
expression on naYve CD8+ T cells was lower in IL-13 -/-, IL-4 -/- and STAT6 -/- BALB/c 
mice compared to BALB/c WT mice (figure 3.5), in these studies, lower IL-4Ra 
expression on naYve CD8+ T cells correlated with the enhancement in the anti-viral IFN-
+TN + + y F-a CD8 T cell responses. 
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Figure 3.7. IL-4 and IL-13 dampen polyfunctional (IFN-y+ TNF-a+) CD8+ T cell 
numbers following VV-WR infection. IL-13 -/-, IL-4 -/-, STAT6 -/- and WT BALB/c 
mice were infected with 3 x 106 PFU of VV-WR or kept as unimmunized controls for 7 
days prior to sacrifice and analysis using ICS after in vitro peptide stimulation. A, 
Representative dot plots showing IFN-y and TNF-a expression on gated CD8+ 
splenocytes from VV-WR infected mice of the indicated genetic background following 
in vitro stimulation of splenocytes with the indicated peptides. B, Mean (n = 6) total 
f d d "fi + + + + + number o K A521s-s3 or L F226-34 spec1 1c CD8 IFN-y or CD8 IFN-y TNF-a 
splenocytes from the indicated mice infected with VV-WR. C, Mean (n = 6) proportion 
of Kd A5275_83 or L dF226_34 specific CD8+ IFN-y + splenocytes that also produced TNF-a 
from the indicated mice infected with VV -WR. The data presented in all panels are 
representative of at least two independent. Error bars depict the SEM and statistical 
significance was determined using a one-way ANOV A (Dunnett' s Multiple 
Comparison) relative to WT control mice(* - p < 0.05 ; *** - p < 0.001). 
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Figure 3.8. STAT6 is required for IL-4 mediated attrition of VY-specific CD8+ T 
cell responses. WT and ST AT6 -!- BALB/c mice were infected with 5 x 106 PFU of 
VV-HA, VV-HA-IL-4 or kept unimmunized for 7 days prior to sacrifice and analysis 
using ICS after in vitro peptide stimulation. A and B, Representative dot plots showing 
IFN-y and TNF-a expression on gated CDS+ splenocytes from infected BALB/c WT 
(A) or BALB/c STAT6 -!- (B) mice following in vitro stimulation of splenocytes with 
the indicated peptides. C, The mean (n = 4-5) number of cytokine producing Kd A5275_83 
or L dF226_34 specific CDS+ splenocytes and the mean (n = 4-5) proportion of CDS+ 
splenocytes that produced TNF-a in addition to IFN-y from WT (top row of plots) or 
STA T6 -!- (bottom row of plots) BALB/c mice infected with the indicated virus. The 
data are representative of two independent experiments and the error bars depict the 
SEM. One-way ANOV A (Dunnett' s Multiple Comparison) was used to determine 
statistical significance of the data relative to VV-HA infected mice(* - p < 0.05; ** - p 
< 0.01 ; *** - p < 0.001). 
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Consistent with the above findings, infection of BALB/c WT mice with VV-HA-IL-4 
compared to VV-HA control infection significantly reduced the numbers of IFN-y + and 
IFN-y + TNF-a + Kd A5275_83 or L dF226_34 specific CD8+ T cells (figure 3.8A and 3.8C). 
The proportion of KdA5275_33 or LdF226-34 specific CD8+ T cells that expressed TNF-a 
in addition to IFN-y was also significantly reduced in BALB/c WT mice infected with 
VV-HA-IL-4 compared to VV-HA (figure 3.8A and 3.8C). Unlike that observed with 
BALB/c WT mice, infection of BALB/c STAT6 -!- mice with VV-HA-IL-4 compared to 
VV-HA control did not impair the IFN-y and TNF-a cytokine production capacity of 
Kd A521s-s3 or L dF226-34 specific CD8+ T cells (figure 3.8B and 3.8C). Thus, elevation 
of IL-4Ra expression on CD8+ T cells during virus infection strongly correlated with 
the reduction of anti-viral IFN-y + TNF-a + CD8+ T cell responses. 
3.3 Discussion 
Results clearly indicated that amongst the different IL-4/IL-13 receptor components 
only cell surface IL-4Ra expression was significantly down-regulated on activated 
CD8+ T cells following virus infection IL-4, IL-13 and STAT6 were required to elevate 
IL-4Ra expression on naYve CD8+ T cells, but not IFN-y. VV-HA-IL-4 infection studies 
showed that IL-4 and STAT6 were required to up-regulate IL-4Ra expression on naYve 
and effector CD8+ T cells. In all these studies higher IL-4Ra expression on CD8+ T 
cells strongly correlated with the reduction in polyfunctional or IFN-y + TNF-a + anti-
viral CD8+ T cells. Thus, it is plausible to propose that regulation of IL-4Ra expression 
during virus infection plays an important role in regulating the quality of anti-viral 
CD8+ T cell immunity. 
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Contrary to suggestions from other reports [Graber et al., 1998; Wills-Karp and 
Finkelman, 2008], data in the current study showed that IL-13Ra 1 is ubiquitously 
expressed on the cell surface of T cells as well as B cells, NK cells and DCs. The reason 
for this discrepancy is unclear, but it is most likely due to the lack of specific 
monoclonal antibodies used to detect surface expression of this receptor [Graber et al., 
1998]. Similar ubiquitous expression on immune cells was also observed with respect to 
IL-4Ra, ye, and IL-13Ra2. However, following virus infection only IL-4Ra was 
notably differentially regulated on certain immune cell subsets (i.e. CD4+ T cells, CD8+ 
T cells and DCs). The mechanisms responsible for regulating IL-4Ra expression on 
CD4 + T cells and DCs following virus infection were not investigated in this study and 
warrants further investigation especially given the importance of these cell subsets in 
driving immune responses that help control intracellular pathogens [Seder et al., 2008; 
Kroger et al., 2008]. 
In an acute LCMV adoptive transfer model, Wherry et al [2007] have reported changes 
in many cellular markers, including IL-4Ra expression on transferred LCMV DbGP33-
specific transgenic P14 CD8+ T cells. In their model, IL-4Ra expression was down-
regulated on LCMV DbGP33-specific CD8+ T cells following acute and chronic LCMV 
infection. These findings are consistent with the findings of the current study. However, 
unlike the current study, Wherry et al [2007] did not investigate the factors responsible 
for regulating IL-4 Ra expression on polyclonal CD8+ T cells or the implications of 
regulating this receptor on CD8+ T cell functionality following virus infection in WT 
. 
mice. 
IL-4 can induce the activation of STATl, STAT3, STATS and STAT6 on naYve and 
activated CD8+ T cells in vitro [ Acacia de Sa Pinheiro et al., 2007], but the current 
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infection studies with VV-HA-IL-4 suggest that STAT6 was indispensible for IL-4 
mediated up-regulation of cell surface IL-4Ra expression on na:ive and effector CDS+ T 
cells. Even in na:ive gene knockout mice STAT6 signaling, which appeared to be 
optimal in the presence of both IL-4 and IL-13 , was required to maintain high levels of 
cell surface IL-4Ra expression on CDS+ T cells. Thus, IL-4 and/or IL-13 signaling 
through STAT6 appears to be important in maintaining high levels of IL-4Ra 
expression on na:ive CDS+ T cells even when no pathogen is encountered. Furthermore, 
this signaling mechanism appears to also be important in elevating IL-4 Ra expression 
on na:ive and effector CDS+ T cells in vivo following virus infection. However, a caveat 
in this interpretation is that deficiency of ST AT6 in other cells may play a role in 
regulating IL-4 Ra expression levels on CDS+ T cells. 
Previous infection studies with VV-HA-IL-4 or recombinant ectromelia virus encoding 
IL-4 suggest that IL-4 dampened the effector function capacity of anti-viral CDS+ T 
cells and enhanced viral pathogenesis [Sharma et al., 1996; Jackson et al., 2001]. In 
chronic HIV progressors, HIV-specific CDS+ T cells with reduced cytolytic capacity 
have been reported to express IL-4 [Maggi et al. , 1994]. In our laboratory, following 
HIV -1 recombinant pox-viral prime-boost vaccination, both IL-4 and IL-13 were found 
to dampen the avidity of HIV-specific CDS+ T cells [Ranasinghe et al. , 2009]. 
However, none of the above studies have monitored the expression of IL-4Ra in 
conjunction with the anti-viral effector functions on CDS+ T cells. This was addressed 
this in the current study and the data suggest that enhancing CDS+ T cell responsiveness 
to IL-4 and/or IL-13 via STAT6 dependent up-regulation of IL-4Ra expression can 
exacerbate the quality (IFN-y and TNF-a cytokine production) of anti-viral CDS+ T cell 
immunity. 
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Paradoxical to these studies, our laboratory findings have also shown that HIV-specific 
CD8+ T cells that developed in IL-4 Ra -/- mice following HIV-1 recombinant prime-
boost vaccination expressed high levels of IL-4 and IL-13, but low levels of IFN-y 
[Ranasinghe et al., 2009]. Other studies using IL-4Ra -/-mice have also shown that IL-
4Ra is required for the maintenance of optimal CD8+ T cell cytotoxicity, IFN-y 
production and memory responses [Marsland et al., 2005; Morrot et al., 2005]. It is 
highly likely that in IL-4 Ra -/-mice, other compensatory mechanisms may play a role in 
dampening CD8+ T cell functionality as Mohrs et al [2000] have shown that IL-4 
producing TH cell (T H2) differentiation can still occur in IL-4Ra -/- mice in vivo. 
Identification of these compensatory mechanisms may not only help understand 
mechanisms important for regulating T cell quality, but also help reconcile the 
paradoxical findings discussed above. 
The exact intracellular mechanisms that facilitate down-regulation of IL-4Ra on CD8+ 
T cells are not clear. The findings from this study suggest that mRNA transcriptional 
regulation is not involved in this process. Given that DOC!(.2 is important for down-
regulating IL-4Ra expression on CD4+ T cells [Tanaka et al., 2007], it would be 
intriguing to investigate whether D0CK2 also plays a similar role in CD8+ T cells. The 
current study also did not investigate how IL-4 and/ or IL-13 mediated elevation of IL-
4 Ra expression on CD8+ T cells act to dampen IFN-y and TNF-a cytokine production 
by anti-viral CD8+ T cells. It is possible that activation of suppressor of cytokine 
signaling-I and -3 on anti-viral CD8+ T cells is important for this effect as IL-4 and IL-
13 mediated activation of these transcription factors have been shown to dampen IFN-y 
and TNF-a cytokine production by keratinocytes [ Albanesi et al., 2007]. IL-4 has also 
been shown to down-regulate the CD8 co-receptor expression levels on antigen-specific 
CD8+ T cells, which dampens the functionality of these cells [Erard et al., 1993; 
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Kienzle et al. , 2005 ; Apte et al. , 201 OJ. Therefore, IL-4 and/or IL-13 mediated 
regulation of the CDS co-receptor expression levels on anti-viral CDS+ T cells may also 
play a role in regulating anti-viral cytokine production and this will be addressed in 
chapter 4. 
To my understanding, this is the first study to evaluate how the different cellular 
receptor components for IL-4 and IL-13 are regulated on CDS+ T cells following virus 
infection. The data from this study suggest that differential regulation of IL-4 Ra, unlike 
other IL-4/IL-13 receptor components (i.e. ye, IL-13Ral and IL-13Ra2) plays a more 
critical role in determining the responsiveness of CDS+ T cells to IL-4 and/or IL-13 in 
order to regulate the quality of anti-viral CDS+ T cell immunity. This is consistent with 
our laboratory studies where IL-4 and IL-13 were shown to play an important role in 
modulating the avidity of HIV-specific CDS+ T cell responses following prime-boost 
vaccination [Ranasinghe et al. , 2007; Ranasinghe et al. , 2009]. Thus, the current 
findings could be exploited to design more effective pox viral-vectored vaccines against 
chronic infections such as HIV-1 where robust CDS+ T cell immunity is required for 
protection. Furthermore, given that IL-4Ra is constitutively expressed on T cells, it may 
easily be used as a novel biomarker to assess T cell quality following vaccination. 
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Chapter 4 
IL-4 and IL-13 Modulation of Anti-Viral CD8+ T 
Cell Avidity Following HIV-1 Recombinant Pox 
Viral Prime-Boost Vaccination 
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Please note that the data presented in this chapter have now been published in: 
Wijesundara DK, RJ Jackson, DC Tscharke and C Ranasinghe. IL-4 and IL-13 
mediated down-regulation of CDS expression levels can dampen anti-viral CDS(+) T 
cell avidity following HIV-1 recombinant pox viral vaccination. Vaccine 2013; 31: 
4548-55. 
4.1 Introduction 
Even though effective anti-retroviral drugs are currently available against HIV-1 
[Thompson et al. , 2010] , developing a vaccine still remains a major priority for slowing 
down the progression of HIV-1 incidences worldwide. Numerous studies have shown 
that elite controllers despite being infected with HIV-1 typically have undetectable 
HIV-1 in the plasma ( <50 RNA copies/ml plasma), which correlates with the presence 
of high avidity and polyfunctional HIV-specific CDS+ T cells [Betts et al., 2006; 
Almeida et al. J 2007; Critchfield et al. 1 2007; Harari et al., 2008]. Recombinant pox 
viruses are extensively used for HIV-1 vaccine development. Therefore, understanding 
factors that could dictate avidity outcomes of anti-viral CDS+ T cells following HIV-1 
recombinant pox viral vaccination could be important for rationale design of effective 
HIV-1 vaccines in the future. 
In the previous chapter, it was discussed that the expression levels of receptors for 
cytokines IL-4 and IL-13 , particularly IL-4Ra was important for modulating anti-viral 
CDS+ T cell avidity. To gain more insight into the roles of IL-4 and IL-13 in modulating 
avidity, the current chapter investigates whether these cytokines regulated the 
expression of T cell associated avidity markers (i.e. TCR, CD8, CD 11 a, CD2 and lck; 
section 1.4) to affect anti-viral CD8+ T cell avidity. These investigations were 
conducted predominantly using published HIV-1 recombinant pox viral prime-boost 
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vaccination strategies in our laboratory ( table 1.5) to help understand how these 
strategies generated high avidity anti-viral CD_8+ T cells. 
4.2 Results 
4. 2.1 IL-4 and JL-13 selectively dampen CD8 densities on HIV-specific CD8+ T cells 
Initially it was examined whether IL-4 and IL-13 regulated the expression of various T 
cell associated molecules, which could dampen the avidity of anti-viral CD8+ T cells 
induced following HIV-1 recombinant pox viral prime-boost vaccination. For this 
purpose, the expression of a representative panel of T cell avidity markers (i.e. TCR, 
CD8, CD1 la, CD2 and lck) were measured on KctGag197-2os specific CD8+ T cells that 
were induced following i.n. FPV-HIV /i.m. VV-HIV vaccination of WT, IL-13 -/-, IL-4 -
/- and STAT6 -/- BALB/c mice (figure 4.1). 
Following HIV-1 recombinant prime boost vaccination, only CD8a and CD8~ levels 
were found to be consistently enhanced on KctGag1 97-2os specific CD8+ T cells obtained 
from gene knockout mice relative to the WT controls (figure 4.18). Although at least 
one report has suggested that high avidity anti-viral CD8+ T cells can enhance the 
expression ratios of CD8~:CD8a [Kroger et al., 2007], these ratios were similar on 
KctGag 197_205 specific CD8+ T cells from all vaccinated animals (figure 4.2A). IL-4 and 
IL-13 mediated reduction of CD8 densities was also observed on Kct A5275_83 specific 
CD8+ T cells 7 days following VV-WR infection (figure 4.28). This suggested that this 
phenomenon was not specific to KctGag197_205 specific CD8+ T cells or the time point 
(i.e. 14 days post booster vaccination) designated to evalulate immunity following 
prime-boost vaccination. 
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Figure 4.1. IL-4 and IL-13 dampen CDS densities on KctGag191-2os specific CDS+ T 
cells following HIV-1 recombinant pox viral prime-boost vaccination. A, 
Representative dot plots showing CD8a and KdGag1 97_205 tetramer expression on gated 
CD8+ splenocytes from mice of the indicated genetic background vaccinated i.n FPV-
HIV /i.m. VV-HIV 14 days apart. The number in the gate of each plot represents the 
percentage of CD8+ splenocytes that recognize the KdGag197_205 tetramer. B, 
Representative histogram plots and the MFI (n = 4) representing the expression of the 
indicated T cell avidity n1arkers on KdGag1 97_205 tetramer specific CD8+ splenocytes 
obtained from vaccinated mice in A. Statistical significance of the data is shown relative 
to BALB/c WT mice using one-way ANOV A (Dunnett's Multiple Comparison). The 
data are representative of at least two independent experiments and the error bars depict 
the SEM. * -p < 0.05 ; ** -p < 0.01. 
78 
A B C D 
** 10.0 
,-., 
0 7.5 0 
->< ._.. 
Cl 5.0 QC) 
Q 
u 
a::I.. 2.5 QC) 
Q 
250 
** 
200 
,-., 
Cl 
QC) 150 Q 
u 
._.. 
100 .... 
.... 
~ 50 
500 D i.m./i.m. 160 
* 
D Control 
* D i.n./i.m. - D IL-13 inhibitor 
- l!ill i.n./i.n. 
,-., 
375 ,-., 120 
Cl Cl 
QC) QC) 
Q Q 
u 250 u 80 ._.. ._.. 
-
.... 
~ ~ 
125 40 
u 
0 0 
Figure 4.2. Up-regulation of CD8 densities, but not CD8~:CD8a ratios are a 
feature of high avidity anti-viral CD8+ T cells following pox virus infection and 
vaccination. A, Mean (n = 4) CD8~:CD8a expression ratios calculated using MFI 
values on KdGag197-2os tetramer specific CD8+ splenocytes from mice prime-boost 
vaccinated in figure 4.1. B, MFI (n = 6) representing CD8a expression on KdA5275_83 
tetramer specific CD8+ splenocytes from mice of the indicated genetic background 
infected for 7 days with 3 x 106 PFU of VV-WR. Statistical significance of the data is 
shown relative to BALB/c WT mice using one-way ANOV A (Dunnett ' s Multiple 
Comparison). C, MFI (n = 4) representing CD8a expression on KdGag1 91-2os tetramer 
specific CD8+ splenocytes from BALB/c WT mice prime-boost vaccinated i.n./i.n. , 
i.n./i.m. or i.m./i.m. 14 days apart with FPV -HIV /VV-HIV. Statistical significance of 
the data is calculated using one-way ANOVA (Tukey's Multiple Comparison). D, MFI 
(n = 4) representing CD8a expression on KdGag 197_205 tetramer specific CD8+ 
splenocytes from BALB/c WT mice prime-boost vaccinated i.n./i.m. with FPV-
HIV /VV -HIV (control) or FPV -HIV -IL-13 Ra2~ 10/VV -HIV -IL-13 Ra2~ 10 (IL-13 
inhibitor vaccine). Statistical significance of the data is calculated using a student's 
unpaired t-test. Data presented in this entire figure is representative of at least two 
independent experiments and the error bars depict the SEM. * -p < 0.05 ; ** -p < 0.01. 
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Our laboratory findings have demonstrated that the avidity of KdGag197-2os specific 
CD8+ T cells can be regulated depending on the route of vaccine delivery (i.e. avidity: 
i.n./i.n. > i.n./i.m. > i.m./i.m.) [Ranasinghe et al. , 2007]. The avidity hierarchy from this 
published report correlated with the CD8 expression levels on KdGag197-2os specific 
CD8+ T cells (i.e. CD8 expression: i.n./i.n. > i.n./i.m. > i.m./i.m.) in the current study 
(figure 4.2C). Fwihermore, our laboratory has recently shown that vaccines that 
transiently inhibit IL-13 activity at the vaccination site can induce high avidity CD8+ T 
cells with better protective efficacy (i.e. avidity and protection: IL-13Ra26 l 0 
adjuvanted IL-13 inhibitor vaccine> control vaccine) [Ranasinghe et al. , 2013]. In the 
current study, compared to the control vaccination (i.n. FPV-HIV /i.m. VV-HIV), IL-13 
inhibitor vaccination strategy (i.n. FPV-HIV-IL-13Ra26l 0/i.m. VV-HIV-IL-
13Ra26l 0) also facilitated the development of KdGag 197_205 specific CD8+ T cells with 
elevated CD8 expression levels (figure 4.2D). Collectively, data suggest that IL-4 
and/or IL-13 can down-regulate CD8 densities, which correlate with reduced avidity on 
anti-viral CD8+ T cells following VV-WR infection and HIV-1 recombinant pox viral 
prime-boost vaccination. 
4.2.2 HIV-specific CD8+ T cells require CD8 for opti,nal cognate pMHC-1 engagement 
Previous studies using CD8 null tetramers and anti-CDS blocking antibodies have 
shown that TCR engagement alone on some anti-viral CD8+ T cell clones is sufficient 
for effector functions and maintaining a high avidity interaction with cognate pMHC-I 
[Choi et al. , 2003 ; Wooldridge et al. , 2003]. Therefore, it was next examined whether 
the availability of CD8 on KdGag197_205 specific CDS+ T cells was important in 
maintaining a high avidity interaction with cognate pMHC-I and for effector functions 
(i.e. cytokine production). 
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In order to achieve the above, splenocytes obtained from i.n. FPV-HIV /i.m. VV-HIV 
vaccinated mice were incubated with CD8 blocking antibodies (i.e. anti-CD8~.2) prior 
to KdGag197_205 tetramer staining or prior to and during KdGag197-2os peptide stimulation 
for ICS (figure 4.3). Data demonstrated a dose dependent reduction of KdGag197-2os 
tetramer engagement with increasing concentrations of anti-CD8~.2 (figure 4.3A). The 
production of cytokines IFN-y, TNF-a and IL-2 was also significantly reduced on CD8+ 
T cells due to CD8 blocking during in vitro KdGag197-2os peptide stimulation (figure 
4.3B). Interestingly, in each vaccinated mouse the dependence of CD8 co-receptor on 
KdGag 197_205 specific CD8+ T cells for cytokine production was as follows: IL-2 > TNF-
a > IFN-y (figure 4.3B). Overall, our data indicated that the availability of CD8 co-
receptor on KdGag197_205 specific CD8+ T cells was crucial for maintaining a high 
avidity interaction with cognate pMHC-I and for effector functions. 
4. 2. 3 Regulation of CD8 densities is a feature of CD8+ T cell polyfunctionality 
Given that there was greater dependence of CD8 co-receptor for production of 
cytokines associated with polyfunctionality (figure 4.3B; e~g . . TNF-a and IL-2), this 
study next examined how CD8 densities were regulated on different polyfunctional 
subsets of HIV-specific CD8+ T cells. Therefore, the CD8 expression levels on IFN-y + 
TNF + IL-2+ -a (highly polyfunctional), IFN-y + TNF-a + (moderately 
polyfunctional) and IFN-y + TNF-a- IL-2- (poorly polyfunctional) KdGag197_205 specific 
CD8+ T cells were measured following i.n. FPV-HIV/i.m. VV-HIV vaccination (figure 
4.4). IFN-y was monitored (figure 4.4B and 4.4C) as a positive control given that 
highly polyfunctional T cells have been reported to produce more IFN-y on a per cell 
basis compared to poorly polyfunctional T cells [Precopio et al., 2007]. There was a 
modest yet statistically insignificant enhancement in CD8 expression levels on 
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KdGag197_205 tetramer Anti-CD8p.2 (µg/ml) 
Figure 4.3. CD8 is required by KctGag197_205 specific CD8+ T cells to optimally 
engage with KctGag197_205 tetramer and for effector functions. Splenocytes obtained 
from i.n. FPV-HIV/i.m. VV-HIV (14 days apart) vaccinated BALB/c WT mice (n = 4-
6) were incubated with 1 µg/ml of purified anti-CD8~.2 prior to (and also during 
stimulation when peptide stimulated) staining with KdGag197_205 tetramer or in vitro 
stimulation with 0.1 µg/ml of KdGag197_205 peptide for ICS. A, Representative histogram 
plot (left panel) or mean (n = 4) percentage of maximum KdGag197_205 tetramer binding 
(right panel) on KdGag191-2os tetramer specific CD8+ splenocytes is shown. The numbers 
in the histogram plot represents the concentration (µg/ml) of anti-CD8~.2 used for CD8 
blocking. B, Percentage of maximum cytokine producing CD8+ splenocytes after CD8 
blocking of splenocytes during in vitro KdGag 197_205 peptide stimulation. Each line is 
representative of the responses from a single vaccinated mouse and the maximum 
response (100%) is the response resulting in the absence of CD8 blocking. The data is 
representative of at least three independent experiments and the error bars when shown 
depict the SEM. 
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moderately polyfunctional cells compared to poorly polyfunctional cells (figure 4.48 
and 4.4C). However, greatly elevated IFN-y, CD8a and CD8~ densities were detected 
in highly polyfunctional compared to poorly/moderately polyfunctional cells (figure 
4.48 and 4.4C). On the contrary, elevation of lck expression was not a feature of 
moderately or highly polyfunctional cells suggesting that there was no generic up-
regulation of avidity markers supporting enhancement in polyfunctionality (figure 4.48 
and 4.4C). 
Given that IL-4 and IL-13 reduced CD8 densities on anti-viral CD8+ T cells (figure 
4.1), this study next examined whether this reduction also affected the establishment of 
highly polyfunctional CD8+ T cells following prime-boost vaccination. It was observed 
that greater proportion of IFN-y producing KdGag 197_205 specific CD8+ T cells expressed 
TNF-a and IL-2 in IL-13 -1-, IL-4 -!- and STAT6 -!- BALB/c mice compared to WT 
controls (figure 4.5A and 4.58). Furthermore, the absolute numbers of IFN-y + TNF-a + 
IL-2+ KdGag191-2os specific CD8+ T cells were also enhanced in the gene knockout mice 
(figure 4.SC). Overall, increasing CD8 densities appeared to be a feature of anti-viral 
CD8+ T cells that were highly polyfunctional following HIV-1 recombinant pox viral 
prime-boost vaccination. 
4.2.4 IL-4 and IL-13 mediated CD8 density regulation on HIV-specific CD8+T cells 
modulate T cell avidity/polyfunctionality 
This study next examined whether IL-4 and IL-13 mediated reduction of CD8 densities 
could also dampen the avidity of HIV -specific CD8+ T cells from WT controls 
compared to IL-13 -/-, IL-4 -/- and ST AT6 -/- BALB/c mice. For this purpose, splenocytes 
from i.n. FPV-HIV/i.m. VV-HIV vaccinated mice were incubated with or without anti-
CD8~.2 prior to conducting an ICS for measuring polyfunctionality or tetramer 
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Figure 4.4. Enhancement of CD8 densities correlates with enhancement in cytokine 
polyfunctionality of HIV-specific CD8+ T cells from IDV-1 recombinant pox viral 
prime-boost vaccinated mice. Splenocytes from i.n. FPV-HIV/i.m. VV-HIV (14 days 
apart) vaccinated BALB/c WT mice (n = 4) were stimulated in vitro with 0.1 µg/ml of 
KdGag197_205 peptide and analyzed for expression of CD8a, CD8~, lck and IFN-y on 
cytokine producing CD8+ T cells. A, Representative dot plots from a peptide 
unstimulated or stimulated culture where IFN-y+ TNF-a- IL-2-, IFN-y+ TNF-a+ IL-2-
and IFN-y+ TNF-a+ IL-2+ CD8+ T cells were gated for analysis. B, Representative 
histogram plots and the MFI showing the expression of CD8a, CD8~, lck and IFN-y on 
different polyfunctional populations of KdGag197_205 specific CD8+ T cells. Each line is 
representative of an individual mouse from a total of four mice -examined. Data 
presented in this figure is representative of at least two independent experiments. A 
paired t-test was used to determine the statistical significance of the data. ns - p > 0.05; 
* -p < 0.05; ** -p < 0.01 ; *** -p < 0.001. 
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Figure 4.5. IL-4 and IL-13 dampen the establishment of highly polyfunctional 
KdGag191-2os specific CD8+ T cells following HIV-1 recombinant pox viral prime-
boost vaccination. Splenocytes from i.n. FPV-HIV/i.m. VV-HIV (14 days apart) 
vaccinated mice were stimulated in vitro with 0.1 µg/ml of KdGag 197_205 peptide for ICS 
analysis. A, Representative dot plots showing IFN-y and CD8a expression (top row of 
plots) on gated CD8+ splenocytes or TNF-a and IL-2 production (bottom row of plots) 
on gated CDS+ IFN-y + splenocytes from vaccinated mice of the indicated genetic 
background. B, The mean (n = 5) proportion of TNF-a and IL-2 producing CDS+ IFN-
y + splenocytes and the mean (n = 5) absolute numbers of CDS+ IFN-y + TNF-a + IL-2+ 
splenocytes for the mice vaccinated in A. Statistical significance of the data is shown 
relative to BALB/c WT mice using one-way ANOV A (Dunnett's Multiple Comparison) 
* -p < 0.05; ** -p < 0.01. 
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dissociation assay for measuring avidity. The rationale here was that if reduction of 
CD8 densities on HIV-specific CD8+ T cells was important then blocking CD8 
availability for tetramer engagement and cytokine production should abrogate avidity 
differences observed between IL-13 -/-, IL-4 -/- and STAT6 -/- BALB/c mice and WT 
controls. 
CD8 blocking of splenocytes from all vaccinated mice reduced the amount of KdGag197_ 
205 tetramer engagement following tetramer dissociation and polyfunctionality of 
KdGag197_205 specific CD8+ T cells during in vitro KdGag197-2os peptide stimulation 
(figure 4.6). Furthermore, statistically significant reduction in KdGag 197_205 tetramer 
engagement of CD8+ T cells from WT mice was not observed relative to the gene 
knockout mice vvhen CD8 was blocked on splenocytes during tetramer dissociation 
(figure 4.6A). Statistically significant reduction in the proportions of IFN-y + KdGag197_ 
20s specific CD8+ T cells that produced TNF-a and IL-2 was also not observed in 
vaccinated WT mice relative to gene knockout mice when CD8 was blocked on 
splenocytes during KdGag197_205 peptide stimulation (figure 4.6B). Thus, IL-4 and IL-13 
mediated down-regulation of CD8 densities appears to be important in reducing avidity 
and polyfunctionality of KdGag191-2os specific CD8+ T cells. 
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Figure 4.6. IL-4 and IL-13 can regulate CD8 expression levels and modulate T cell 
quality of KctGag197-2os specific CD8+ T cells following HIV-1 recombinant pox viral 
prime-boost vaccination. WT, IL-13 -/-, IL-4 -/- and STAT6 -/- BALB/c mice (n = 5-8) 
were i.n. FPV-HIV/i.m. VV-HIV (14 days apart) vaccinated. Splenocytes from these 
mice with (1 µg/ml anti-CD8~.2) or without (mock) CD8 blocking were stimulated in 
vitro using 0.1 µg/ml of KdGag1 97-2os peptide for ICS or stained using KdGag197-2os 
tetramer for tetramer dissociation. A, Mean (n = 8) percentage of maximum KdGag 197_ 
20s tetramer binding of CD8+ T cells following tetramer dissociation for 60 minutes in 
the absence or presence of CD8 blocking. B, The mean (n = 5) proportion of CD8+ IFN-
y + splenocytes that also produced TNF-a and IL-2 in the absence or presence of CD8 
blocking of splenocytes during KdGag 197_205 peptide stimulation. The data in this figure 
is representative of 2-3 independent experiments and the error bars depict the SEM. 
Statistical significance of the data was calculated using a one-way ANOV A relative to 
WT mice (Dunnett ' s Multiple Comparison). * -p < 0.05; ** -p < 0.01. 
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4.3. Discussion 
Due to the disappointing outcomes of numerous HIV -1 vaccine trials conducted thus 
far, development of more efficacious HIV -1 vaccines is a necessity for slowing the 
global progression of HIV-1. This requires the fundamental understanding of 
mechanisms that generate favourable immune outcomes following vaccination. Our 
laboratory has previously shown that following HIV-1 recombinant pox viral prime-
boost vaccination, IL-4 and IL-13 can dampen the avidity of HIV-specific CD8+ T cells 
[Ranasinghe et al. , 2009; Ranasinghe et al. , 2013]. The current study reports that IL-4 
and IL-13 can dampen CD8 densities on anti-viral CD8+ T cells following HIV-1 
recombinant pox viral prime-boost vaccination. Furthermore, reduced expression levels 
of CD8 were a feature of low avidity anti-viral CD8+ T cells that developed in various 
pox virus infection and vaccination settings. 
Data in the current study suggest that IL-4 and IL-13 selectively regulated the 
expression levels of CD8, but not other T cell avidity markers such as TCR, CD2, 
CDl la and lck on anti-viral CD8+ T cells following HIV-1 recombinant pox viral 
prime-boost vaccination. This is also the first report to show the involvement of IL-13 
in regulating CD8 densities on anti-viral CD8+ T cells. Previous reports have shown that 
IL-4 exposure in vitro and in vivo can down-regulate CD8 expression levels to reduce 
the cytolytic capacity of effector CD8+ T cells [Kienzle et al. , 2005 ; Apte et al. , 2008]. 
Furthermore, IFN-I have also been shown to reduce CD8 expression levels and avidity 
of anti-viral CD8+ T cells [Xiao et al. , 2007]. These reports are consistent with the 
findings of the current study where reduction of CD8 densities also appeared to reduce 
the avidity and functional capacity of anti-viral CD8+ T cells. It would be of great 
interest for future investigations to also examine whether IFN-I cooperate 
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synergistically with IL-4 and/or IL-13 in down-regulating CD8 densities on anti-viral 
CD8+ T cells following pox virus infection or vaccination. 
Belyakov et al [2007; 2008] have shown that mucosal vaccination strategies are 
efficient in inducing high avidity anti-viral CD8+ T cells particularly at tissues closer to 
the sites of immunization. Several other studies suggest that mucosal vaccination 
strategies can induce high avidity CD8+ T cells that can protect macaques against SIV 
challenge [Belyakov et al., 2001; Kent et al., 2005; Belyakov et al., 2006]. In the 
current study mucosal HIV -1 recombinant pox viral prime-boost vaccination strategies 
were found to enhance CD8 densities on HIV -specific CD8+ T cells, which correlated 
with T cell avidity. Ranasinghe et al [2013] and the current study collectively show that 
mucosal vaccination strategies that temporarily inhibit IL-13 function (i.e. IL-
13Ra2~10 adjuvanted vaccines) can enhance CD8 densities and avidity of HIV-specific 
CD8+ T cells with better protective outcomes. These findings are consistent with Ahlers 
et al [2002] study showing that immunization of mice with peptide vaccine constructs 
in conjunction with granulocyte macrophage colony stimulating factor and IL-13Ra2-
Fc antibodies can enhance the cytotoxic activity of HIV-specific CD8+ T cells and 
protection. Interestingly, Isakov et al [2011] have shown that IL-15 plays an important 
role in enhancing avidity of anti-viral CD8+ T cells following mucosal immunization, 
which is consistent with Oh et al [2004] where IL-15 was shown to enhance CD8 
densities and avidity of anti-viral CD8+ T cells. Therefore, development of vaccines that 
prevent significant down-regulation of CD8 densities on antigen-specific CD8+ T cells 
offer exciting prospects for developing efficacious vaccines against intracellular 
mucosal pathogens such as HIV -1. 
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Even though polyfunctionality correlates with avidity of anti-viral CD8+ T cells [La 
Gruta et al. , 2006; Almeida et al. , 2007], regulation of molecules that can affect both T 
cell avidity and polyfunctionality is not well understood. In the current study, 
enhancement in CD8 densities highly correlated with enhancement in avidity and 
polyfunctionality of HIV -specific CD8+ T cells following pox viral vaccination. 
Furthermore, blocking CD8 availability significantly reduced the polyfunctional 
capacity and avidity of HIV-specific CD8+ T cells. Thus, monitoring CD8 expression 
levels could be used as a predictor of both avidity and polyfunctional capacity of anti-
viral CD8+ T cells especially for CD8 dependent T cell clones following pox viral 
vaccination. The caveat here is that IFN-y, TNF -a and IL-2 production by LCMV -
specific monoclonal P 14 transgenic CD8+ T cells can occur independently of CD8, 
especially during later stages of LCMV infection [Slifka and Whitton, 2001 ; Kerry et 
al. , 2005]. Therefore, it is likely that according to different viruses and/or the infection 
state (i.e. acute or chronic) multiple redundant mechanisms may be involved in 
regulating polyfunctionality of anti-viral CD8+ T cells. These mechanisms may include 
regulation of lipid raft formation [Cawthon et al. , 2004] , TCR clonotypes [Kedzierska 
et al., 2005] , IL-4Ra (chapter 3), lck [Slifka and Whitton, 2001] and IL-15 receptor a 
[Oh et al. , 2004] on CD8+ T cells. 
The current study did not examine whether IL-4 and IL-13 reduced CD8 densities on 
anti-viral CD8+ T cells during long-term memory phases even though effector phase 
data suggests that this phenomenon is not specific to an epitope or a particular time 
point following immunization. However, whether this phenomenon operates during 
long-term memory phases to regulate the quality of anti-viral CD8+ T cell responses 
requires further investigation. Another caveat in the current study is that anti-CD8 
antibodies were used to determine the dependence of avidity and functional quality on 
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the CD8 co-receptor molecules of CD8+ T cells. There have been no reports to suggest 
that the anti-CD8~.2 antibodies (clone 53-5.8) used in the current study can sterically 
hinder other interactions (i.e. TCR with pMHC-I) of CD8+ T cells. In fact, several 
publications have used this particular antibody to determine the dependence of survival 
and functionality on CD8 co-receptor molecules of CD8+ T cells [Slifka and Whitton, 
2001; La Gruta et al. , 2006; Takeda and Jameson, 2009; Loi et al. , 2013]. In an ideal 
scenario, however, these experiments are best performed using CD8 null tetramers as 
additional controls given that these tetramers specifically do not allow CD8 co-receptor 
engagement with pMHC-I [Choi et al., 2003]. 
Most HIV-1 vaccination strategies to date have mainly focused on the induction of 
either neutralizing antibodies or CD8+ T cell responses against HIV-1. However, as 
discussed in section 1.5.4 the induction of heterosubtypic immunity (both neutralizing 
antibody and CD8+ T cell responses) is expected to be beneficial in generating optimal 
protective immunity against HIV-1. The findings from the current study suggest that 
HIV-1 recombinant pox viral vaccination strategies that inhibit IL-13 function can 
enhance the quality of anti-viral CD8+ T cell immunity most likely through up-
regulation of CD8 densities on anti-viral CD8+ T cells [Ranasinghe et al. , 2013]. Such 
vaccination strategies could also enhance the quality of antibody immunity, as IL-4 and 
IL-13 are known to mediate isotype switching of antibodies to IgE; enhanced IgE 
production has co1Telated with enhanced pathogenesis of HIV-1 [Vigano et al., 1995; 
Ouaaz et al. , 1996; Oettgen et al. , 2000]. 
In conclusion, the current study suggest that IL-4/IL-13 could mediate down-regulation 
of CD8 expression levels as a likely mechanism to dampen the avidity/polyfunctionality 
of anti-viral CD8+ T cells. Furthermore, recombinant HIV-1 pox viral mucosal 
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vaccination strategies that can transiently inhibit IL-13 activity at the vaccination site 
can enhance CD8 densities and avidity of anti-viral CD8+ T cells. It is plausible to 
propose that in the absence of IL-4 and IL-13 signalling, anti-viral CD8+ T cells express 
higher amounts of CD8 allowing these cells to build high avidity interactions with 
cognate pMHC-I complexes presented on virus-infected cells. This should facilitate 
high avidity CD8+ T cells to maintain more durable interactions with virus-infected 
cells allowing them to exert effector functions efficiently. Thus, vaccine strategies that 
inhibit IL-4/IL-l 3 activity offer great promise for future vaccines against many chronic 
infections including HIV-1 that require high avidity CD8+ T cells for protective 
immunity. 
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Chapter 5 
The FT A Assay for Assessing T Cell Magnitude, 
Avidity and Epitope Cross-Reactivity In Vivo 
94 
The data in this chapter is now under review in the journal Vaccine: 
Wijesundara DK, C Ranasinghe, J Price, RJ Jackson, I Atmosukarto, CR Parish and BJ 
Quah. Use of an in vivo FT A assay to assess the magnitude, functional avidity and epitope 
variant cross-reactivity of T cell responses following HIV-1 recombinant pox virus 
vaccination. Manuscript submitted to Vaccine (Manuscript ID: JVAC-D-13-01113Rl) . 
5.1 Introduction 
The induction of high avidity, polyfunctional and epitope variant cross-reactive anti-
viral CD8+ T cell responses particularly against conserved HIV-1 epitopes ( e.g. Gag) 
have been associated with superior HIV-1 control in elite controllers [Pontesilli et al. , 
1998; Betts et al. , 2006; Almeida et al. , 2007; Critchfield et al. , 2007; Ferre et al. , 2010; 
Berger et al. , 2011; Mothe et al. , 2012; Turk et al. , 2013]. Hence, it can be postulated 
that measuring and inducing high avidity CD8+ T cell responses in vivo are necessary 
for effective and rationale HIV-1 vaccine design. As described in section 1.9, many of 
the current T cell based-assays provide limited capacity to measure avidity and epitope 
variant cross-reactivity, which led us to develop the FTA technology to make these 
measurements in vivo [Quah et al. , 2012]. Furthermore, this technique also allows for 
the measurements of TH cell responses based on the ability of TH cells to activate ( e.g. 
up-regulate CD69 expression) FTA B cells pulsed with peptides [Quah et al. , 2013]. 
In previous studies Ranasinghe et al [2006; 2007; 2011] have established that the 
combination of vaccine route and the order in which HIV -1 recombinant pox viral 
vaccine vectors are delivered in prime-boost regimens can alter HIV-specific CD8+ T 
cell immunity and avidity. In the current study, the FT A assay was used to further 
clarify which vaccine vector combinations induced the best T cell immune responses 
(e.g. avidity, cross-reactivity and helper capacity) in vivo following HIV-1 recombinant 
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pox viral prime-boost vaccination. The primary aim of the current study was to test the 
feasibility of using the FTA assay as a high-throughput tool to screen for the most 
effective HIV-1 vaccination strategies that can induce desired T cell responses in vivo. 
5.2 Results 
5. 2.1 Utility of the FTA Assay in measuring T cell responses in vivo 
To establish the utility of the FT A assay as a screening tool to measure T cell effector 
responses in a reproducible manner, six BALB/c mice were immunized with VV-WR 
and in vivo CD8+ T cell killing responses were measured 7 days p.i. using the FTA. 
Responses were assessed against immunodominant VV F2L (L dF226_34) , subdominant 
VV A52R (Kd A5275_83 ) and F2L mut (MV A homologue of F2L; section 2.3) epitopes. 
A generic schematic representation of the steps involved in this technique is depicted in 
figure 5.1. As anticipated killing responses were not detected against the HIV neg 
control epitope, but were obvious against F2L and A52R epitopes (Figure 5.2A-B). 
Despite not being expressed by VV-WR, epitope variant cross-reactive CD8+ T cell 
killing responses against the F2L mut epitope were detected in all VV-WR infected 
animals (Figure 5.2A). Furthermore, the magnitude of the killing responses against the 
epitopes were as follows: F2L > A52R > F2L mut. In addition to the AUC 
measurements describing the magnitude of the killing responses (figure 5.2B), the ECso 
measurements were also made to determine the avidity of the CD8+ T cell responses 
(figure 5.2C). This analysis revealed that CD8+ T cells required 10 times the amount of 
A52R peptide and 70 times the amount of F2L mut peptide to generate half maximal 
killing compared to F2L (Figure 5.2C). Overall, the above data provide an example of 
the utility of the FT A assay in reproducibly measuring magnitude, avidity and epitope 
variant cross-reactivity of CD8+ T cell killing responses in vivo. 
,, 
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5.2.2 Screening FPV- and VV-based prime-boost vaccine regzmens using the FTA 
assay 
Having established the reproducibility and utility of the FT A assay, we then applied the 
technique to screen various HIV -1 recombinant pox virus prime-boost vaccination 
regimens for their ability to induce T cell responses. To assess this we generated a 
vaccine regimen matrix based on all the combinations (i.e. 24 combinations) of two 
vectors FPV-HIV and VV-HIV given either i.n. or i.m. (table 5.1). To comprehensively 
assess these regimens, immune responses to seven different T cell epitopes were 
investigated. This included CD8+ T cell epitopes from VV (F2L, F2L mut) as positive 
controls and HIV (Gag (KctGag197_205), Pol, Env and .Gag mut) as described in section 
2.3. Also a HIV Gag TH eptiope (section 2.3) that allow activation of B cell targets in 
the FTA was included to measure TH cell responses (figure 5.lC) [Quah et al., 2013]. 
A representative experiment from three independent experiments is shown in 
supplementary figure 4 and 5 and includes data from six intra-animal replicates (6048 
data points per experiment). Due to the large amount of data generated in this instance, 
AUC values were calculated for responses against each epitope and depicted as a heat 
map to allow trends to be revealed more easily (figure 5.3A). Killing responses from 
several vaccine regimens were clearly detectable against the Gag and even the Gag mut 
epitopes, but only negligible killing responses were detected against Pol and Env 
epitopes (figure 5.3). Interestingly, the magnitude of the killing responses against Gag, 
Gag mut, F2L and F2L mut epitopes were greatest in the heterologous FPV-HIV /VV-
HIV prime-boost regimens (figure 5.3). The responses against the Gag mut are also 
indicative of Gag epitope variant cross-reactive CD8+ T cell responses following 
vaccination. Furthermore, FPV-HIV /VV-HIV regimens also gave robust TH cell 
responses against the Gag TH epitope (figure 5.3). 
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Figure 5.1. Schematic representation of a 252-parameter FTA assay. 5 x 107 
splenocytes from mice were labeled with combinations of CTV (0 nM, 350 nM, 1295 
nM, 4792 nM, 17729 nM and 65595 nM), CFSE (0 nM, 79 nM, 315 nM, 1106 nM, 
3859 nM, 13505 nM and 47269 nM) and CPD (0 nM, 106 nM, 690 nM, 2738 nM, 
10262 nM and 38506 nM) to generate 252 discernable cell clusters. Cell clusters were 
pulsed with MHC-binding peptides (as outlined in figure 5.3) to generate a panel of 42 
peptide pulsed clusters and this repeated six times to generate six intra-animal repeats 
(i.e., 252 target cell clusters in total). Target cells were also labeled with Dil for 
discrimination from host splenocytes (not shown). A, FTA cells were injected i.v. into 
host mice that had 6 days earlier been vaccinated with VV-HIV or left unimmunized as 
a control. 18 how·s after FT A injection, splenocytes were collected and target cells 
delineated fron1 host splenocytes by Dil label using flow cytometry (not shown). B, 2D 
plots of the fluorescence intensities of a panel of 42 VV F2L peptide-pulsed clusters 
from unirnmunized (left plots) and vaccinated (right plots) mice and an associated 
histogram analysis of clusters pulsed with titrated amounts of VV F2L peptide. The 
disappearance of target cells in these clusters in vaccinated mice relative to 
unimmunized controls reveals specific killing of F2L peptide pulsed targets. C, An 
example of histogram analysis of the FTA T helper assay where B220+ FT A cells 
pulsed with the Gag TH cell peptides were assessed for CD69 up-regulation in 
vaccinated and unimmunized mice. 
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Figure 5.2. The FT A assay can reproducibly measure magnitude, functional 
avidity and epitope variant cross-reactivity of CD8+ T cells in vivo. Six BALB/c 
mice were immunized i.p. with 5 x 106 PFU of VV-WR. FTA was constructed using 
mouse splenocytes and comprised of FT A cells pulsed with six different concentrations 
of the MHC-I binding peptides F2L, F2L mut, A52R, and HIV neg (as a negative 
control). FTA target cells were injected i.v. into infected mice 6 days p.i. and after 18 
hours in vivo percent specific killing calculated for FT A target cells from harvested 
spleens. A, In vivo killing responses from six infected mice where each plot represents 
an individual mouse. B, Summary of responses depicted in A from all mice with means 
(n = 6) of percent specific killing. C, Mean (n = 6) AUC measurements from percent 
specific killing response curves in A. D, Mean (n = 6) EC50 of the killing response in C. 
The e1Tor bars depict the SEM and the p values were calculated using a one-way 
ANOV A (Tukey's Multiple Comparison). Data is representative of several independent 
experiments. * - p < 0.05. 
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Figure 5.3. Heat map screen of the magnitude of in vivo killing of the indicated 
peptide-pulsed targets. BALB/c WT mice were vaccinated with 24 different vaccine 
regimens as shown in table 5.1 and T cell responses were assessed using a 252-
parameter FT A comprised of cells pulsed with six concentrations of F2L, F2L mut, 
Gag, Gag mut, Pol, Env and Gag TH· FTA target cells were injected i.v. into vaccinated 
mice 6 days post vaccination and responses assessed after 18 hours in vivo using 
harvested spleens for analysis using flow cytometry. AUC were then calculated and 
portrayed as a heat map where darkest shading indicates highest magnitude and lightest 
shading indicates lowest magnitude T cell responses. Data is representative of three 
independent experiments. 
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From the above analysis, it was also apparent that FPV -HIV NV-HIV and VV-
HIV /FPV-HIV regimen clusters gave strong killer and helper T cell responses against 
Gag epitopes (figure 5.3 and 5.4A). When evaluating the avidity for the killer 
responses against Gag and Gag mut epitopes, FPV-HIV /VV-HIV prime-boost 
vaccination cluster had the lowest EC50 and therefore the highest avidity killing 
responses (figure 5.4B). There appeared to be no vaccination route dependent trends in 
the killing responses for the FPV-HIVNV-HIV cluster (figure 5.4B). Interestingly, 
there was evidence to suggest that the VV -HIV /FPV-HIV heterologous prime-boost 
vaccination strategy benefited from the i.m. boost with FPV-HIV as this regimen gave a 
comparable avidity killing response against Gag epitopes to that of the FPV -HIV NV-
HIV cluster. Whilst the FPV-HIVNV-HIV and VV-HIV/FPV-HIV generated TH cell 
responses against Gag TH epitope, negligible EC50 changes were apparent with TH cell 
responses in these clusters (figure 5.4). Overall, the best vaccine strategy in terms of 
inducing high avidity killer and helper T cell responses appeared to be regimens 
comprised of FPV-HIV priming followed by VV-HIV booster vaccination. 
5. 2. 3 Liposome boosting improves the niagnitude, functional avidity and epitope variant 
cross-reactivity of CD8+ T cell responses 
FPV -HIV NV -HIV vaccination generated robust kiiling responses against Gag and Gag 
mut epitopes, but these responses were consistently lower compared to the responses 
against immunodominant VV F2L epitope (figure 5.5A and 5.5B). This was also 
observed with respect to the avidity of CDS+ T cell responses. For example, whilst the 
i.n. FPV-HIV/i.m. VV-HIV regimen typically generated a IO-fold and 40-fold avidity 
enhancement against Gag epitope and Gag mut epitope respectively compared to 
vaccination with VV -HIV alone, the avidity of these responses was still lower than 
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Figure 5.4. Magnitude, avidity and cross-reactivity of Gag-specific T cell responses 
for the experiment described in figure 5.3. Mice vaccinated from figure 5.3 were 
further analyzed for magnitude (A) and avidity (B) to determine vaccine clusters that 
were robust at inducing high avidity and cross-reactive Gag-specific T cell responses in 
vivo. Two separate clusters (FPV-HIV /VY-HIV (red box)) and VY-HIV /FPV-HIV 
(green box)) were identified as the most effective vaccine regimens in generating high 
avidity and cross-reactive Gag-specific CD8+ T cell responses in vivo. 
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Figure 5.5. Tertiary vaccination with liposomes improves the magnitude, 
functional avidity and epitope variant cross-reactivity of CD8+ T cell responses 
following prime-boost vaccination. Mice were vaccinated i.n. with FPV-HIV, i.m. 
with VV-HIV, and/or i.v. with liposomes (containing 35 mg of Gag mut and 1 mg of 
LPS per dose). Liposome booster vaccinations were given 4 weeks post the i.m. VV-
HIV and 6 weeks post the i.n. FPV-HIV vaccinations. T cell responses were assessed 
using 252-parameter FT As as in figure 5.3. A, Percent specific killing of FTA in vivo 
by CDS+ T cells induced by prime, boost, and/or tertiary liposome vaccination regimens 
showing killing responses to F2L, F2L mut, HIV Gag and HIV Gag mut epitopes. B, 
Mean (n = 6) for the killing responses against the epitopes shown in A. C, Mean (n = 6) 
AUC values for the killing responses shown in B. D, Mean (n = 6) EC50 values for the 
killing responses shown in A. The error bars depict the SEM and the p values were 
calculated using Mann-Whitney nonparametric two-tailed t-test. ** -p < 0.01. 
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responses against F2L epitope 1n seven independent experiments (representative 
example give in figure 5.50). Therefore, the use of a peptide (HIV Gag mut)-liposome 
( section 2.5) construct for vaccination was investigated to determine whether the 
avidity of HIV Gag-specific CDS+ T cell responses could be improved beyond that of 
F2L-specific CDS+ T cells. Gag mut peptide was chosen such that the highest avidity 
and cross-reactive Gag-specific CDS+ T cells could be expanded. 
Peptide-liposome constructs and LPS were administered i.v. 6 weeks post i.n. FPV-HIV 
vaccination and 4 weeks post i.m. VV -HIV booster vaccination. T cell responses were 
assessed using the FTA T cell assay 7 days post peptide-liposome booster vaccination 
(figure 5.5). As controls, mice were also vaccinated with liposome constructs alone, 
which generated negligible killing responses against all epitopes (figure 5.5A-B). 
When liposome constructs were included as a tertiary vaccination for the i.n. FPV-
HIV /i.m. VY-HIV regimen, the magnitude of the killing responses against Gag and the 
Gag mut epitopes was higher than that of the i.n. FPV-HIV /i.m. VY-HIV vaccination 
alone (figure 5.5C). Interestingly, following i.n. FPV-HIV /i.m. VY-HIV /liposomes 
vaccination the magnitude and the avidity (EC50) of the killing responses against Gag 
and F2L epitopes were similar (figure 5.5). The EC50 values of the killing responses 
against Gag and Gag mut epitopes revealed a three-fold enhancement in the i.n. FPV-
HIV /i.m. VY-HIV /liposomes regimen relative to the i.n. FPV-HIV /i.m. VY-HIV 
regimen (figure 5.50). Collectively, data suggests that a liposomal booster vaccination 
can be used to futiher enhance the magnitude, avidity and epitope variant cross-
reactivity of desired ( e.g. Gag-specific) CDS+ T cell responses. 
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5.3 Discussion 
Here the use of a high-throughput multi-parameter in vivo assay with the capacity to 
measure magnitude, avidity and epitope variant cross-reactivity of T cell responses in 
vivo following HIV-1 vaccination was described. This assay is unique in that it allows 
the simultaneous measurement of killing and helper activity against numerous target 
cells pulsed with a broad concentration range of several different MHC-I/II binding 
peptides in vivo. Furthermore, previously developed in vivo CD8+ T cell killing assays 
[Oehen et al., 1997; Barchet et al. , 2000] can only measure the magnitude of killing 
responses in a single animal whereas the FT A can also provide detailed measurements 
of avidity and epitope variant cross-reactivity in a single animal. In vitro assays such as 
the 51Cr-release, ICS and ELISPOT peptide dilution assays, typically require ex vivo 
stimulation of host effector T cells. Such stimulation may also result in changes in 
avidity at a population level due to preferential outgrowth of high avidity effector T 
cells [Yerly et al. , 2008]. Thus, the FTA assay has an excellent capacity with distinct 
advantages to measure multiple parameters of T cell responses in a single animal in 
VlVO. 
The versatility of the FT A assay allowed the comprehensive screening of T cell 
responses generated from 24 different vaccination regimens against 7 distinct viral 
epitopes (Gag, Gag TH, Gag mut, Pol, Env, F2L and F2L mut). From this analysis, 
heterologous prime-boost vaccination regimens, particularly FPV -HIV /VV -HIV 
regimens were found to be the most effective strategy in generating high magnitude of 
anti-viral CD8+ T cell responses with high avidity and epitope variant cross-reactivity in 
vivo. The FTA assay cannot be used to quantify the absolute numbers of responding 
CD8+ T cells, but our laboratory using in vitro assays such as tetramer 
staining/dissociation assays and ICS have addressed this aspect. The findings from these 
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assays also suggest that the FPV-HIV NV-HIV vaccination regimen was most effective 
in generating high avidity Gag-specific CD8+ T cell responses [Ranasinghe et al. , 2006; 
Ranasinghe et al. , 2007; Ranasinghe et al. , 2011]. These findings also demonstrate that 
vector combinations in pox viral prime-boost vaccination regimens play an important 
role in determining vaccine efficacy and CD8+ T cell avidity. Despite the consisting of 
findings with respect to the choice of vector combinations, the FTA assay did not 
indicate avidity differences on Gag-specific CD8+ T cells when FPV-HIV was delivered 
i.n. or i.m. in the FPV-HIVNV-HIV regimen. This is in contrast to Ranasinghe et al 
[2007] where data from tetramer dissociation assays demonstrated that i.n. compared to 
i.m. priming with FPV-HIV was more efficient in generating high avidity Gag-specific 
CD8+ T cells in the FPV-HIVNV-HIV regimen [Ranasinghe et al. , 2007]. The reasons 
for this discrepancy are unclear and it could suggest that data from in vitro assays such 
as tetramer dissociation do not always correlate with the data from FTA assays. 
However, it remains to be seen whether this discrepancy is due to the fact that killing 
responses using the FT A assay were measured 18 hours post target cells transfer instead 
of an earlier time point where high avidity CD8+ T cells more actively participate in 
killing than low avidity CD8+ T cells. 
More and more studies are indicating that vaccines can induce T cell responses to cross-
reactive epitopes and techniques to evaluate these parameters are of great importance 
when dealing with diseases like HIV-I. Broad epitope variant cross-reactivity of CD8+ 
T cells have been observed in elite controllers [Mothe et al. , 2012]. Similar findings 
have been reported in hepatitis C virus patients, where clearance of the virus was 
associated with increased epitope variant cross-reactivity and heightened avidity of 
CD8+ T cells [Yerly et al., 2008]. In the current study, the FPV-HIVNV-HIV 
vaccination regimen was also extremely efficient in generating highly cross-reactive 
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CD8+ T cell responses against Gag mut epitope. Collectively, the current study 
demonstrates that FPV-HIV NV-HIV heterologous prime-boost vaccination regimens 
have the hallmarks of an efficacious vaccination strategy that could induce robust 
protective immunity. 
Another important finding from the current study was that CD8+ T cell killing responses 
generated by FPV-HIV /VV -HIV vaccination were further enhanced when liposomes 
carrying HIV-1 epitopes were used as a tertiary vaccination. Specifically, this allowed 
the avidity of the killing responses against Gag and Gag mut to be increased by about 
three fold from the FPV-HIV NV-HIV vaccination alone. In various prime-boost 
vaccination studies, a tertiary booster has been shown to enhance both T and B cell 
immunity [Stambas et al. , 2005]. Also, in the recent Thai RV144 trial, recombinant 
HIV -1 canary pox priming followed by a HIV -1 protein booster vaccination yielded 
immune outcomes with a 30% protective efficacy [Rerks-Ngarm et al. , 2009]. 
The ref ore, there the use of liposome vectors could be extremely beneficial for vaccine 
regimens requiring multiple booster vaccinations, especially when anti-vector immunity 
is of concern. Liposomes are also safe in humans and can be engineered to express 
tailor-made epitopes, danger signals and targeting motifs to amplify immune responses 
generated previously using recombinant DNA or viral vectors [Immordino et al., 2006]. 
However, the use of safer immune adjuvants other than LPS is recommended for 
application in humans. 
There are few caveats with the FT A assay in its current form for evaluating HIV-1 
vaccine efficacy. One caveat of the FT A assay is that it relies on target cells that are 
pulsed with designated viral peptides rather than target cells infected with HIV -1 where 
the relative expression of these designated peptides could be significantly different. 
1 1 1 
Furthermore, in the current assay killing responses were measured 18 hours post-
transfer of target cells. Given that high avidity CDS+ T cells are expected to kill virus-
infected target cells early compared to low avidity counterparts (figure 1.3), it will also 
be important to determine whether the kinetics of the killing responses can change the 
avidity and magnitude measurements made using this assay. These caveats could be 
better addressed if the FTA was optimised for use in MHC-I matched macaques instead 
of mice where the killing responses against SIV-infected target cells could be 
monitored. Along with relevant SIV protective studies, this is expected to improve the 
translatability of the findings from the FT A assay regarding the efficacy of vaccination 
regimens in facilitating the development of high avidity CDS+ T cells with a great 
potential to control HIV-1 infections. 
In conclusion, using the novel FTA assay a combination of HIV-1 recombinant pox 
viral prime-boost regimens were evaluated for their ability to generate robust anti-viral 
T cell responses in vivo. In this study, it was found that the magnitude, avidity and 
epitope variant cross-reactivity of CDS+ T cells in vivo are dependent on the vaccine 
vector combination used for vaccination. Out of the 24 vaccine combinations tested, 
FPV-HIV NV-HIV vaccination strategies induced the best immune outcomes. 
Moreover, liposome tertiary vaccination further enhanced the magnitude, avidity and 
epitope cross-reactivity of CDS+ T cell immunity, which offers great prospects for 
future vaccine development. Overall, data suggest that the FTA assay is an extremely 
valuable and cost-effective tool that can be used for large scale screening of vaccine 
combinations in vivo for pre-clinical testing. 
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Chapter 6 
General Discussion 
113 
6.1 Synopsis 
After over three decades since the discovery of HIV -1 , a vaccine against this deadly 
virus is currently not available. Rationale HIV-1 vaccine design is a difficult prospect 
given the rapid mutation rate and latency capabilities of this virus [Chomont et al., 
2009; McMichael et al., 2010]. However, developing HIV-1 vaccination strategies that 
can induce broadly neutralizing antibodies, ADCC and high avidity anti-viral CDS+ T 
cells offer hope especially given that these immune components correlate with HIV-1 
resistance ( e.g. in elite controllers) [Walker et al. , 2009; Haynes et al., 2012; Julien et 
al. , 2013 ; Liao et al. , 2013; Critchfield et al., 2007; Turk et al. , 2013]. Our laboratory 
has previously shown that systemic (i.m./i.m.) HIV -1 vaccination strategies promote 
greater induction of IL-4 and IL-13 to dampen anti-viral CDS+ T cell avidity compared 
to mucosal (i.n./i.n. and i.n./i.m.) HIV-1 vaccination strategies [Ranasinghe et al., 2007; 
Ranasinghe et al. , 2009]. Based on these findings our laboratory also constructed novel 
and protective IL-13Ra211 l O adjuvanted HIV-1 pox viral vaccines that transiently 
inhibit IL-13 function and enhance the avidity of anti-viral CDS+ T cells following 
mucosal vaccination [Ranasinghe et al. , 2013]. To understand how our mucosal HIV-1 
vaccinations strategies generated favourable immune outcomes, the current PhD 
investigated how IL-4 and IL-13 dampened anti-viral CDS+ T cell avidity. Furthermore, 
the use of a novel FT A assay as a screening tool to select HIV-1 pox viral vaccine 
strategies that can induce high avidity T cell responses in vivo was also evaluated. The 
key findings from these studies and their ramifications will be discussed in this chapter. 
6.2 IL-4Ra is an important regulator of anti-viral CD8+ T cell avidity 
In order to understand how IL-4 and IL-13 dampened avidity of anti-viral CDS+ T cells, 
we initially evaluated the expression of receptors for these cytokines on immune cells 
, 
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following virus infection. Given that cytokines require receptors to exert their biological 
effects, it was hypothesized that regulation of receptors in a manner that allow CD8+ T 
cells to reduce the responsiveness to IL-4 and/or IL-13 can enhance the avidity of CD8+ 
T cells. In support of this hypothesis, our findings suggest that down-regulation of IL-
4 Ra, the common signalling receptor subunit of IL-4 and IL-13 [Wills-Karp and 
Finkelman, 2008], on naYve CD8+ T cells was important for priming high avidity and 
polyfunctional anti-viral CD8+ T cell responses. This conclusion is consistent with 
previous in vitro studies showing that IL-4 during polyclonal stimulation primes naYve 
CD8+ T cells to become poorly functional effector cells [Erard et al., 1993; Kienzle et 
al., 2005]. The PhD studies also showed that even on effector CD8+ T cells greater 
down-regulation of IL-4Ra expression following cognate antigen encounter correlated 
with significant enhancement in IFN-y and TNF-a production during virus infection. 
These findings are in agreement with previous reports where heightened IL-4 and IL-13 
responses in the context of tumour and virus infections were shown to dampen 
functional capacity and avidity of effector CD8+ T cells [Sharma et al. , 1996; Jackson et 
al., 2001; Apte et al., 2008; Apte et al., 201 O; Ranasinghe et al., 2009; Ranasinghe et 
al., 2013]. Thus, down-regulating IL-4Ra expression on naYve CD8+ T cells appeared · 
to be important for priming high avidity anti-viral CD8+ T cells and for established anti-
viral effector CD8+ T cells to maintain high avidity anti-viral responses during the 
course of a virus infection. 
Elevation of IL-4 Ra expression on CD8+ T cells could also play an important role in 
immune evasion of HIV -1 during natural infections. There are reports showing that 
enhanced IgE levels are featured in patients with poor HIV-1 prognosis [Israel-Biet et 
al., 1992, Vigano et al., 1995, Rancinan et al., 1998]. Similarly anti-viral IgE responses 
have been associated with enhanced pathogenesis of respiratory syncytial virus [Russi et 
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al., 1993 ; Dakhama et al. , 2009]. IL-4 and IL-13 are required for IgE synthesis in 
humans and IL-4 producing CD8+ T cells are emiched in HIV-1 infected patients 
[Maggi et al., 1994; Punnonen et al. , 1997]. Therefore, it is possible that IL-4 and IL-13 
induced following HIV-1 infection could in tum elevate IL-4Ra expression on CD8+ T 
cells and reduce CD8+ T cell avidity as a mechanism to evade anti-viral CD8+ T cells 
immunity. 
6.3 IL-4 and IL-13 regulate CDS densities to dampen anti-viral CDS+ T cell avidity 
The above observations suggest that reducing the responsiveness to IL-4 and IL-13 via 
down-regulation of IL-4Ra is important for enhancing the avidity of anti-viral CD8+ T 
cell responses. It was next evaluated whether these cytokines affected the expression of 
T-cell associated molecules (e.g. CD1 la, CD2, TCR, CD8 and lck) on anti-viral CD8+ 
T cells that participate in maintaining high avidity cell-cell interactions with APCs. 
Ranasinghe et al [2007; 2009] have identified differences in CD8+ T cell avidity 
following HIV-1 vaccination using tetramer dissociation assays; these assays 
distinguish avidity based on the strength of tetramer engagement with the TCR and/or 
CD8 co-receptor. This led to the hypothesis that IL-4 and IL-13 can reduce the affinity 
and/or the expression levels of TCR and/or CD8 co-receptor for down-regulating 
avidity of HIV-specific CD8+ T cells. Indeed, it was found that IL-4 and IL-13 
selectively dampen CD8 expression levels, which also dampen the avidity and 
polyfunctionality of HIV-specific CD8+ T cells following i.n. FPV-HIV /i.m. VV-HIV 
vaccination. 
A few repo1is following influenza virus infections have suggested that the usage of 
certain TCR clonotype (e.g. TCR V~7) is characteristic of high avidity CD8+ T cells 
,, 
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[Kedzierska et al., 2005; Kedzierska et al., 2008]. Although in the current study TCR 
clonotypes were not evaluated, data suggest that enhancement in CD8 densities was 
sufficient to enhance avidity of HIV-specific CD8+ T cells that developed in vaccinated 
IL-4 -1-, IL-13 -/- and STAT6 -/- mice relative to WT controls. Previous reports are also in 
agreement with the above findings where anti-viral CD8+ T cell avidity was shown to 
be up-regulated due to enhancement in CD8, but not TCR densities following pox viral 
infection [Oh et al., 2004; Xiao et al., 2007]. Overall, data suggest that IL-4 and IL-13 
mediated regulation of CD8 densities is an important determinant of CD8+ T cell avidity 
following pox viral infection and HIV-1 recombinant pox viral prime-boost vaccination. 
6.4 How does IL-4 and IL-13 responsiveness affect anti-viral CD8+ T cell avidity? 
The data obtained from the virus infection and vaccination studies can be used to 
propose a tentative model where anti-viral CD8+ T cell avidity could be regulated based 
on IL-4 and IL-13 responsiveness. Previously, Xiao et al [2007] have shown that CD8 
densities are down-regulated on anti-viral CD8+ T cells following cognate antigen 
encounter during pox virus infections. In chapter 3, it was -shown that naYve CD8+ T 
cells in the absence ofIL-4 and IL-13 signalling (i.e. in IL-4 -/-, IL-13 -/- and STAT6 -/-
mice) expressed lower levels of IL-4 Ra making them less responsive to these cytokines 
during T cell priming. Therefore, it is plausible to propose that IL-4 and IL-13 
signalling through activation of ST AT6 promotes greater down-regulation of CD8 
densities on naYve CD8+ T cells following cognate antigen encounter during pox virus 
infection and vaccination. Consequently, anti-viral effector CD8+ T cells that develop 
with reduced CD8 densities have poor polyfunctionality and avidity. It has been shown 
that heterologous mucosal HIV-1/SIV prime-boost vaccination regimens are most 
effective in preserving avidity and protective capacity of anti-viral CD8+ T cells [Kent 
et al., 2005; Belyakov et al., 2006; Belyakov et al., 2008; Ranasinghe et al., 2007; 
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Ranasinghe et al. , 2011; Ranasinghe et al. , 2013]. Therefore, vaccines (e.g. IL-13 
inhibitor) that minimise down-regulation of CD8 densities on HIV-specific CD8+ T 
cells even following mucosa! vaccination hold great potential in facilitating protective 
CD8+ T cell immunity against HIV-1. 
6.5 FTA assay is a valuable screening tool for assaying CD8+ T cell avidity in vivo 
Previously, it was discussed that identifying mechanisms that can regulate anti-viral 
CD8+ T cell avidity is important for developing more efficacious HIV-1 vaccines. In 
particular, the importance of regulating IL-4Ra and CD8 co-receptor expression levels 
on anti-viral CD8+ T cells was discussed. Another important aspect for developing more 
efficacious HIV-1 vaccines is to develop assays that evaluate CD8+ T cell avidity in 
vivo in pre-clinical models. Therefore, as the final study during the PhD project the use 
of a novel FT A assay was evaluated for this purpose. 
Interestingly, the FT A assay efficiently isolated clusters of HIV-1 recombinant pox viral 
vaccination strategies that were most effective in generating high avidity T cell 
responses zn vivo (e.g. heterologous FPV-HIVNV-HIV vaccination strategies). The 
high avidity Gag-specific CD8+ T cell killing responses induced following FPV-
HIV./VV-HIV vaccination regimens also exhibited superior epitope cross-reactivity. 
Various T cell responses (avidity, epitope cross-reactivity and helper activity) using the 
FT A were also measured against a range of peptide pulsed target cells (> 200) in the 
same HIV -1 vaccinated animal allowing for thorough screening of large number of 
vaccine strategies in a cost-effective manner. Overall, the development of the FTA 
assay is a significant advancement in the field of HIV-1 vaccine development given that 
this is the only assay that can be used to comprehensively measure functional avidity of 
anti-viral CD8+ T cell responses in vivo following JilV-1 vaccination. 
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A few caveats for using this assay include that HIV- I infected target cells could not be 
used in mice and that the kinetics of killing are also expected to provide useful 
information regarding how efficient high avidity CD8+ T cells are in clearing virus-
infected targets. Overall, the studies conducted clearly demonstrated the utility and 
effectiveness of the FT A assay in measuring various T cell quality parameters that are 
representative hallmarks of protective immunity against viral infections in vivo. 
Furthermore, the FTA assay could be utilized to develop effective prime-boost 
vaccination strategies for novel vaccines/vectors that aim to induce high avidity T cell 
responses in vivo using pre-clinical models. 
6.6 Significance of the PhD 
Effective HIV- I prophylactic vaccines will require the induction of high avidity HIV-
specific CD8+ T cells and robust antibody responses. Given that HIV- I transmissions 
occur mainly through a single founder virus [Keele et al., 2008], it is important to have 
these responses at transmission sites ( e.g. genito-rectal mucosa in case of sexual 
transmissions and systemic compartments in case of blood transfusions). This should 
serve to minimise systemic viral spread and establishment of latent reservoirs. The 
findings from our laboratory thus far suggest that vaccination strategies, which 
minimise IL-4/IL-13 responses and maintain high CD8 densities on anti-viral CD8+ T 
cells are beneficial for this purpose. In particular, i.n. FPV-HIV /i.m. VV-HIV and 
mucosal IL-13 inhibitor vaccination strategies were extremely effective at inducing high 
avidity HIV -specific CD8+ T cells at both mucosal and systemic compartments 
[Ranasinghe et al. , 2007; Ranasinghe et al. , 2013]. Preliminary findings from our 
laboratory also suggest that mucosal IL-13 inhibitor vaccines promote anti-viral IgG 
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responses. Matthew Worley, current student in the laboratory, is evaluating whether 
these IgG responses are similar to those that have correlated with ADCC responses and 
protection against HIV-1 [Haynes et al., 2012; Tomaras et al., 2013]. Therefore, 
mucosal HIV-1 recombinant pox viral vaccination strategies that inhibit IL-13 
responses have provided promising outcomes for developing prophylactic HIV -1 
vaccmes. 
Currently, about 34 million people are infected with HIV-1 globally and therapeutic 
approaches to cure these individuals are desperately in need. Mucosal HIV-1 
recombinant pox viral vaccination strategies that induce high avidity HIV-specific 
CD8+ T cells may also be used for this purpose. Shan et al [2012] have shown that 
autologous Gag-specific CD8+ T cells are required to efficiently clear latently-infected 
CD4+ T cells following re-activation in vitro. Recently, histone deacetylase inhibitors 
such as vorinostat and pano binostat have emerged to be promising drugs for 
reactivating latency on CD4+ T cells and thereby exposing these cells to the immune 
system [Archin et al. , 2012; Rasmussen et al. , 2013]. Therefore, vaccination of HIV-
infected individuals with i.n./i.m. HIV-1 IL-13 inhibitor vaccines prior to treatment with 
histone deacetylase inhibitors might facilitate the rapid clearance of latently infected 
CD4 + T cell reservoirs. A caveat with this strategy is the presence of immune exhausted 
CD8+ T cells in HIV-1 infected patients, but evaluation of these approaches should help 
develop a complete cure for HIV-1 infected patients. 
6. 7 Future directions 
It is intriguing why up-regulation of IL-4Ra, but not down-regulation of this receptor 
on CD8+ T cells was dependent on STAT6 following virus infection in vivo. Down-
regulation of IL-4Ra on CD4+ T cells has previouslY, been described to be dependent on 
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D0CK2 [Tanaka et al., 2007]. Even though the dependence of IL-4Ra down-regulation 
on D0CK2 has not been explored on CD8+ T cells, future investigations could benefit 
from examining whether D0CK2 and ST AT6 play antagonizing roles in regulation of 
IL-4 Ra expression on CD8+ T cells. This will provide more insight as to how IL-4 Ra 
expression and CD8+ T cell avidity are regulated. 
Whether reduced responsiveness to IL-4 and IL-13 in a CD8+ T cell autonomous 
manner is sufficient to enhance anti-viral CD8+ T cell avidity was not evaluated in the 
current PhD project. This is important for identifying whether cell types other than 
CD8+ T cells can contribute to regulating CD8 expression levels and avidity of anti-
viral CD8+ T cells. To evaluate this initially, infection or vaccination of mice where IL-
4Ra is mainly or exclusively deficient only in CD8+ T cells is required. These mice 
could be generated using bone marrow chimeras (i.e. chimeras between CD8a -!- and 
IL-4 Ra -/- mice) or ere-lox system as done in Dewals et al [2009]. 
Given the ethical, technical and sampling limitations it is more difficult to conduct 
elaborate functional assays using human specimens compared to laboratory animals. 
Therefore, there is a constant requirement for identifying novel yet reliable biomarkers 
that are descriptive of lymphocyte functions especially CD8+ T cell avidity in the 
context of HIV -1 infections. Monitoring cell surface IL-4 Ra expression levels on naYve 
CD8+ T cells might be ideal and descriptive for predicting avidity of HIV-specific CD8+ 
T cells in HIV-1 infected patients. To address this possibility, initially IL-4Ra 
expression levels on naYve CD8+ T cells from elite controllers (where elite control is 
associated with enhanced HIV -specific CD8+ T cell avidity) and HIV -1 progressors 
should be monitored. It can be hypothesized that IL-4 Ra expression levels will be lower 
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on na:ive CDS+ T cells or at least on naYve precursors of HIV-specific CDS+ T cells from 
elite controllers relative to HIV-I progressors. 
Studies in our laboratory have demonstrated that mucosal (i.n./i.m.) IL-13 inhibitor 
vaccination strategies can protect mice against a lethal recombinant influenza-HIV virus 
mucosa! challenge [Ranasinghe et al. , 2013]. It is also important to determine whether 
such mucosal vaccination strategies can be protective in the context of SIV infections in 
1nacaques in order to thoroughly evaluate the translational prospects of these vaccines. 
It will be intriguing to dete1mine whether regulation of IL-4Ra and CDS co-receptor 
levels on na:ive and SIV-specific CDS+ T cells following IL-13 inhibitor vaccination can 
be predictive of protective outcomes and avidity of SIV-specific CDS+ T cells. Our 
laboratory is currently constructing vaccines for use in macaques for this purpose, 
which will hopefully allow for the full evaluation of our vaccines ' translational potential 
for testing in human clinical trials in the near future. 
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Supplementary figure 1. The importance of TCR signaling and IL-4 in regulating 
IL-4Ra expression of CD8+ T cells in vitro. F ACS sorted CD4410 CD8+ splenocytes 
from naYve BALB/c mice were cultured for 8 hours in presence or absence of 0.1 ng/ml 
of recombinant murine IL-4 using microwells (2 x 104 cells/well) coated with anti-
CD3E or not (unstimulated). Subsequently, cultured splenocytes were analyzed using 
flow cytometry for IL-4Ra expression. A, Representative histogram plots showing IL-
4Ra expression on CD8+ splenocytes cultured in the presence or absence of anti-CD3E 
+ IL-4. B, MFI (n = 4) representing IL-4Ra expression on CD8+ splenocytes cultured in 
the presence or absence of anti-CD3E ± IL-4. The data presented is representative of 
two independent experiments and the error bars depict the SEM. One-way ANOVA 
(Tukey ' s Multiple Comparison) was used to determine statistical significance of the 
data(*** - p < 0.001 ). 
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Supplementary figure 2. The absence of IL-4 and IL-13 does not affect the in vivo 
IL-4Ra expression on naive B cells, CD4+ T cells, NK cells and DCs. Splenocytes 
from naYve mice were isolate and analyzed using flow cytometry for IL-4 Ra 
expression. A, Representative histogram plots showing IL-4Ra expression on the 
indicated immune cell subset. B, MFI (n = 3) representing IL-4Ra expression on the 
indicated immune cell subset. The data presented is representative of at least two 
independent experiments and the en·or bars depict the SEM. One-way ANOVA 
(Dunnett's Multiple Comparison) was used to determine statistical significance of the 
data relative to WT mice(*** - p < 0.001). 
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Supplementary figure 3. Down-regulation of IL-4Ra expression on CD8+ T 
following VV infection is not due to transcriptional regulation. Splenocytes from 7 
days VV-WR infected (3 x 106 PFU/mouse) or unimmunized BALB/c WT mice were 
F ACS sorted for quantitative real-time PCR analysis as described in the materials and 
methods. A, Representative density plots showing IL-4Ra and CD8a expression on 
gated CD8+ splenocytes from mice infected with VV -WR or kept as unimmunized. B, 
Mean (n = 4-6) fold change in mRNA transcript levels of IL-4Ra and GzmB on F ACS 
sorted IL-4Ra10 and IL-4Rahi cells from VY-infected mice with respect to the mRNA 
transcript levels of F ACS sorted CD8+ T cells from unimmunized mice. The data shown 
is representative two independent experiments and the error bars depict the SEM. 
Statistical significance of the data was determined relative to IL-4Rahi cells using a 
student's unpaired t-test (*** - p < 0.001). 
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Supplementary figure 4. Killing responses data used to construct the heat map 
shown from the experiment in figure 5.3. 
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Supplementary figure 5. Gag TH data used to construct the heat map shown from 
the experiment in figure 5.3. 
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